Home The Word Brain My Amedeo FAQ Privacy About


Hanzi Hunter

Learning 500 Chinese characters in 30 days is possible.

Abstract • About

  Otorhinolaryngology

  Free Subscription


Articles published in Oral Oncol

Retrieve available abstracts of 518 articles:
HTML format



Single Articles


    April 2026
  1. HUANG YJ, Fang KC, Tsai MH, Chuang HC, et al
    Swallowing-related outcomes and organ-at-risk dosimetry after proton versus photon radiotherapy in nasopharyngeal carcinoma.
    Oral Oncol. 2026;175:107906.
    PubMed     Abstract available


  2. CRACCHIOLO JR, Kavanagh F, Starc MT, Scholfield D, et al
    Defining response-adapted surgery after neoadjuvant systemic therapy in sinonasal squamous cell carcinoma.
    Oral Oncol. 2026;175:107882.
    PubMed     Abstract available


  3. PARK H, Kim BR, Yoo JH, Kim SW, et al
    Clinical implication of the 2025 ATA risk stratification in follicular thyroid carcinoma: A comparison with the 2015 ATA risk stratification.
    Oral Oncol. 2026;175:107912.
    PubMed     Abstract available


  4. MANFUSO A, Cirignaco G, Cocis S, Volpe F, et al
    Selective tracheostomy in oral cancer reconstruction with myomucosal flaps: Outcomes and an appraisal of published risk scores.
    Oral Oncol. 2026;175:107916.
    PubMed     Abstract available


  5. NGO DQ, Le DT, Ngo QX, Le QV, et al
    Surgical outcomes of modified versus conventional transoral endoscopic thyroidectomy vestibular approach for papillary thyroid carcinoma.
    Oral Oncol. 2026;175:107908.
    PubMed     Abstract available


    March 2026
  6. JAGADEESHA S, Lamenza F, Upadhaya P, Chung C, et al
    Sex-based immune differences influence tumor progression in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;176:107929.
    PubMed     Abstract available


  7. DOU K, Liu D, Shi Y, Qin H, et al
    Can the submandibular gland be preserved during neck dissection in patients with oral squamous cell carcinoma?A systematic review and meta-analysis.
    Oral Oncol. 2026;176:107913.
    PubMed     Abstract available


  8. DAI WF, Nguyen L, Liu N, Chan KK, et al
    Corrigendum to "Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study" [Oral Oncol. 173 (2026) 107851].
    Oral Oncol. 2026 Mar 5:107919. doi: 10.1016/j.oraloncology.2026.107919.
    PubMed    


  9. SHIMIZU T, Takahashi H, Tada H, Chikamatsu K, et al
    Integrative analysis of aging-related immune parameters reveals prognostic and immunotherapeutic implications in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;176:107914.
    PubMed     Abstract available


  10. CHU F, Benzi P, Tagliabue M, Mossinelli C, et al
    Rare laryngeal tumors: A retrospective bicentric study on 74 patients and systematic review.
    Oral Oncol. 2026;174:107852.
    PubMed     Abstract available


  11. WOJTERA BP, Beharry A, Salati V, Lambercy K, et al
    Long-term swallowing outcomes following transoral robotic surgery for oropharyngeal cancer - Five years and beyond.
    Oral Oncol. 2026;174:107876.
    PubMed     Abstract available


    February 2026
  12. ZHAO ZY, He SQ, Liu GY, Lv SH, et al
    Efficacy of radiotherapy to metastatic lesion in de novo metastatic nasopharyngeal carcinoma patients: A multicenter, propensity score matching study.
    Oral Oncol. 2026;175:107907.
    PubMed     Abstract available


  13. NTOUKAS SM, Mohamad N, Boparai R, Dennett L, et al
    Effects of exercise on health-related fitness and patient-reported outcomes in survivors of head and neck cancer: a systematic review and meta-analysis.
    Oral Oncol. 2026;175:107902.
    PubMed     Abstract available


  14. BHATI M, Bagchi P, Pawar P, Baviskar P, et al
    Aberrant lateral position of external carotid artery, a surgical pitfall during neck dissection.
    Oral Oncol. 2026;175:107905.
    PubMed    


  15. HOLGADO A, Llansana A, Vazquez C, Gallego O, et al
    Identification of prognostic variables in patients with recurrent head and neck squamous cell carcinoma treated with salvage surgery: Implications for treatment with immunotherapy.
    Oral Oncol. 2026;175:107903.
    PubMed     Abstract available


  16. ECONOMOPOULOU P, Pouliakis A, Kyprianou M, Pantazopoulos A, et al
    An observational retro-prospective study on patients with head and neck cancer who contracted COVID-19 (HERODOTUS: head and neck cancERs international cOviD-19 collabOraTion).
    Oral Oncol. 2026;175:107900.
    PubMed     Abstract available


  17. MARGONI A, Papavassiliou KA, Papavassiliou AG
    From heterogeneity to molecular stratification: A multiplex genomic panel for tailored therapy of head and neck squamous cell carcinoma.
    Oral Oncol. 2026;175:107904.
    PubMed     Abstract available


  18. LI C, Xiao X, Jiang H, Li B, et al
    Comparable survival after lobectomy and total thyroidectomy for T3b differentiated thyroid carcinoma: A population-based study.
    Oral Oncol. 2026;175:107891.
    PubMed     Abstract available


  19. XIN Y, Yang L, Liu C, Li D, et al
    Spatial transcriptomics of immune ecotypes for predicting immunotherapy outcomes in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;175:107887.
    PubMed     Abstract available


  20. FAN M, Yin Q, Li L, Lian Q, et al
    Low-dose fractionated radiotherapy combined with induction chemotherapy in high-risk nasopharyngeal carcinoma: An open-label, randomized phase 2 trial.
    Oral Oncol. 2026;175:107888.
    PubMed     Abstract available


  21. BENITES C, White C, Balaguru L, Gonghao L, et al
    Does discharge location following head and neck cancer surgery affect quality outcomes?
    Oral Oncol. 2026;175:107879.
    PubMed     Abstract available


  22. SINGH SP, Prasad S, Dean PM, Kujur AL, et al
    Prognostic significance of extranodal extension in cervical lymph node metastases of head and neck squamous cell carcinoma: A systematic review and meta-analysis with bibliometric overview.
    Oral Oncol. 2026;174:107862.
    PubMed     Abstract available


  23. ZHANG L
    Comment on "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery".
    Oral Oncol. 2026;174:107881.
    PubMed    


  24. ROY P, Weber MB, Gupta R, Kakkar A, et al
    The prognostic significance of the 'Worst Pattern of Invasion' in oral cancers-an international collaborative multicentre analysis.
    Oral Oncol. 2026;174:107874.
    PubMed     Abstract available


  25. TAKAHASHI Y, Bell D, Corona A, Su SY, et al
    Establishment of novel stable human sinonasal NUT carcinoma cell lines.
    Oral Oncol. 2026;173:107828.
    PubMed     Abstract available


    January 2026
  26. HACK S, Karni RJ, Maniaci A, Fundakowski CE, et al
    Evaluation of large language models as decision support tools for head and neck cancer management: A blinded multidisciplinary simulation study.
    Oral Oncol. 2026;174:107877.
    PubMed     Abstract available


  27. WANG N, Gao H, Yu SX, Fan J, et al
    The first report of contralateral parapharyngeal space metastasis of papillary thyroid carcinoma: report of a case.
    Oral Oncol. 2026;174:107865.
    PubMed    


  28. ZHONG J, Chen H, Yan Z, Xu H, et al
    Refinement of N category in version-nine of AJCC/UICC TNM staging system for nasopharyngeal carcinoma based on the international consensus recommendations for diagnosing extranodal extension.
    Oral Oncol. 2026;174:107866.
    PubMed     Abstract available


  29. ALMEIDA ND, Schrand TV, Sullivan D, Yu H, et al
    Prognostic associations of systemic inflammation response index (SIRI) in patients with head and neck cancer: a systematic review and meta-analysis.
    Oral Oncol. 2026;174:107859.
    PubMed     Abstract available


  30. LOVETT JT, Wotman MT, Westra WH, Ahn S, et al
    Long-Term outcomes of induction chemotherapy-guided reduced-dose chemoradiotherapy in poor-risk HPV-Positive oropharyngeal Cancer: Results from the sequential quarterback trials.
    Oral Oncol. 2026;174:107858.
    PubMed     Abstract available


  31. CHENG C, Zhang J
    Advancing methodological rigor in exercise oncology trials for head and neck cancer.
    Oral Oncol. 2026;173:107857.
    PubMed    


  32. CAROSI F, Demurtas S, Ciarfella A, Orlandi E, et al
    Perioperative immunotherapy for head and neck cancer: from early successes to clinical challenges in relapsed and/or metastatic disease.
    Oral Oncol. 2026;173:107853.
    PubMed    


  33. WANG W, Lou Y
    From risk factors to clinical Decisions: Methodological Considerations in Predicting occult metastasis in papillary thyroid carcinoma.
    Oral Oncol. 2026;173:107854.
    PubMed    


  34. SOBY S, Mortensen D, Gothelf A, Gyldenkerne N, et al
    Prognostic significance of p16 and immune cell infiltration in recurrent/metastatic head and neck squamous cell carcinoma treated with PD-1 inhibition: a national DAHANCA cohort study.
    Oral Oncol. 2026;173:107849.
    PubMed     Abstract available


  35. DAI WF, Nguyen L, Liu N, Chan KK, et al
    Real-world effectiveness and healthcare utilization of nivolumab for advanced head and neck cancer: A real-world population-based descriptive study.
    Oral Oncol. 2026;173:107851.
    PubMed     Abstract available


  36. MARGONI A, Papavassiliou KA, Papavassiliou AG
    Harnessing TP53 mutational status to enhance prognostic precision and therapeutic effectiveness in head and neck squamous cell carcinoma.
    Oral Oncol. 2026;173:107846.
    PubMed    


  37. WU WJ, An PG, Zhang ZQ, Shen LH, et al
    Neoadjuvant tislelizumab plus chemotherapy in locally advanced oral and oropharyngeal squamous cell carcinoma: A single-arm phase II clinical trial.
    Oral Oncol. 2026;172:107809.
    PubMed     Abstract available


  38. NIU S, Ding J, Chen H, Zhu Z, et al
    Positron emission tomography-based intratumoral spatial diversity for prognosis in nasopharyngeal carcinoma.
    Oral Oncol. 2026;173:107845.
    PubMed     Abstract available


    December 2025
  39. XIAO G, Ning L, Chen L, Zhang S, et al
    Exercise and quality of life in head and neck squamous cell carcinoma patients receiving neoadjuvant immuno-chemotherapy: A randomized, open-labeled phase II trial.
    Oral Oncol. 2025;173:107844.
    PubMed     Abstract available


  40. JAKOBSEN KK, H Rasmussen J, Melchiors J, Agander TK, et al
    Head and neck cancer trends in Denmark: A nationwide, 40-Year data analysis.
    Oral Oncol. 2025;173:107843.
    PubMed     Abstract available


  41. LECHIEN JR, Paleri V, Baudouin R, Brunet A, et al
    European surgical guidelines: transoral robotic surgery for head and neck cancers.
    Oral Oncol. 2025;173:107826.
    PubMed     Abstract available


  42. CHAUDHRY M, Elfar A, Rowsey K, Neel A, et al
    Safety reporting in head and neck squamous cell carcinoma clinical Trials: A comparative analysis of ClinicalTrials.gov data and published research.
    Oral Oncol. 2025;173:107840.
    PubMed     Abstract available


  43. ZHANG M, Song J, Yuan Y, Cao X, et al
    Ensemble learning-based radiomics model for predicting radiation-induced temporal lobe injury in nasopharyngeal carcinoma.
    Oral Oncol. 2025;173:107841.
    PubMed     Abstract available


  44. PARK SE, Hong SH, Park JO, Kim SY, et al
    Head and neck squamous cell carcinoma following allogeneic bone marrow transplantation: Clinical features, genomic Alterations, and limited efficacy of palliative chemotherapy.
    Oral Oncol. 2025;173:107827.
    PubMed     Abstract available


  45. THIAGARAJAN S, Rukmangathan T, Sharma D, Kakade A, et al
    Prevalence, risk Factors, and quality of life in patients with head and neck lymphedema following treatment for head and neck Cancer: The HeNLy-1 study.
    Oral Oncol. 2025;173:107838.
    PubMed     Abstract available


  46. LIU Q, Wei JN, Zhou JY, Zhang CR, et al
    Development of a simplified scoring system for MRI-detected retropharyngeal lymph node features to optimize AJCC 9th edition N classification in nasopharyngeal carcinoma.
    Oral Oncol. 2025;173:107825.
    PubMed     Abstract available


  47. ZOU C
    Letter to the editor: Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort.
    Oral Oncol. 2025;172:107705.
    PubMed    


  48. CHOW VL, Ho VW, Lo AS
    Trans-hairline robotic neck dissection and robotic microvascular free flap reconstruction in oral cavity cancer.
    Oral Oncol. 2025;172:107819.
    PubMed     Abstract available


  49. YOON HN, Kim JH, Gu D, Lee J, et al
    Patient-derived 3D organoid platform for functional assessment of GPC3-targeted CAR T cell cytotoxic activity in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;172:107814.
    PubMed     Abstract available


  50. SHAIKH MH, Gazala W, Zeng C, Naimi MF, et al
    NOTCH1 loss promotes chemo and radio-resistance in head and neck cancer.
    Oral Oncol. 2025;172:107815.
    PubMed     Abstract available


  51. HACK S, Attal R, Geva K, Farzad A, et al
    Blinded comparative evaluation of GPT-generated, online search-derived, and guideline-based answers for HPV-associated oropharyngeal cancer.
    Oral Oncol. 2025;172:107813.
    PubMed     Abstract available


  52. BARAN E, Lee M, Kamalraj P, Karam I, et al
    Cancer stage documentation and accuracy: Single-center retrospective study on oropharyngeal cancers.
    Oral Oncol. 2025;171:107795.
    PubMed     Abstract available


  53. CHELVARAJAH RC, Huang SH, Su J, Gete M, et al
    Outcomes and characteristics of patients receiving pre-operative versus post-operative radiotherapy for sinonasal squamous cell carcinoma.
    Oral Oncol. 2025;171:107794.
    PubMed     Abstract available


  54. CHONG CY, Young RJ, Lim AM, Pizzolla A, et al
    Evaluating CD103(+) intratumoral immune cell abundance and PD-L1 CPS in primary tumors versus lymph nodes in Human papillomavirus associated oropharyngeal Cancer.
    Oral Oncol. 2025;171:107792.
    PubMed     Abstract available


  55. HIDALGO CM, Hernandez-Herrera GA, Day CN, Olawuni F, et al
    Access to surgery and high-quality radiotherapy for human papillomavirus related oropharynx cancer.
    Oral Oncol. 2025;171:107768.
    PubMed     Abstract available


    November 2025
  56. LECHIEN JR
    Learning process of transoral robotic surgery for head and neck cancers: a scoping review.
    Oral Oncol. 2025;171:107788.
    PubMed     Abstract available


  57. LI M, Zhou Y, Cai M
    Letter to the Editor: A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2025;171:107784.
    PubMed    


  58. OKURA M, Yamakawa N, Otsuru M, Hasegawa T, et al
    T4a classification for oral cancer using mandibular canal invasion instead of bone marrow invasion in the TNM staging system.
    Oral Oncol. 2025;171:107771.
    PubMed     Abstract available


  59. DOERFLER R, Chen J, Kim C, Smith JD, et al
    Integrating artificial intelligence-driven digital pathology and genomics to establish patient-derived organoids as new approach methodologies for drug response in head and neck cancer.
    Oral Oncol. 2025;171:107742.
    PubMed     Abstract available


  60. DIEZ-FRAILE A, Pottel L, Lamoral P, De Backer T, et al
    Age and surgical complexity outperform preoperative Geriatric-8 for 30-day major complications in older head and neck cancer.
    Oral Oncol. 2025;171:107774.
    PubMed    


  61. VAN LOOCKE P, Beuselinck B, Meulemans J, Nuyts S, et al
    Impact of time-of-day administration of immune checkpoint inhibitors on survival outcomes in patients with recurrent/metastatic head and neck cancer (R/M HNSCC): a retrospective cohort study.
    Oral Oncol. 2025;171:107772.
    PubMed    


  62. TIRELLI G, Boscolo-Rizzo P
    Perioperative pembrolizumab and the changing paradigm of adjuvant therapy in head and neck squamous cell carcinoma: the case of T1-2, pN1.
    Oral Oncol. 2025;171:107770.
    PubMed    


  63. MASO V, Lechien JR, Gengler I, Chiesa-Estomba C, et al
    Management of head and neck cancer around the world: an international survey by the world ear, nose, and throat federation.
    Oral Oncol. 2025;171:107766.
    PubMed     Abstract available


  64. WILLIAMS MM, Hanna GJ, Sethi RK, Rettig EM, et al
    Outcomes of oropharyngeal squamous cell carcinoma among patients with lymphoproliferative disorders.
    Oral Oncol. 2025;170:107761.
    PubMed     Abstract available


  65. LI R, Ma S, Tang T, Zhao Y, et al
    Prognostic impact and risk factors of level IV/V lymph nodes metastasis in laryngeal squamous cell carcinoma.
    Oral Oncol. 2025;170:107758.
    PubMed     Abstract available


  66. ZHU AQ, Cassianni CE, Haller T, O'Byrne TJ, et al
    Sensitivity of post-treatment surveillance in detecting recurrence and metastasis in surgically treated HPV-positive oropharyngeal squamous cell carcinoma patients.
    Oral Oncol. 2025;171:107767.
    PubMed     Abstract available


    October 2025
  67. BERTIN B, Kowalski LP, Matos LL
    The low evidence to treat elderly patients with head and neck cancer.
    Oral Oncol. 2025;171:107764.
    PubMed     Abstract available


  68. XIANG N, Li W
    Re: "Patterns of care in de?novo oligo?metastatic and oligo?recurrent head and neck cancers: A HNCIG survey" (Oral oncology).
    Oral Oncol. 2025;171:107749.
    PubMed    


  69. DAS R, Misra SR, Mohapatra SSG
    Refining prognosis and Personalizing Therapy: A Step Forward with Machine learning in HPV-Associated head and neck cancer.
    Oral Oncol. 2025;170:107752.
    PubMed    


  70. LIANG H, Guo Y
    Comment on "Massive nasal bleeding in nasopharyngeal carcinoma": Risk stratification and clinical implications.
    Oral Oncol. 2025;170:107755.
    PubMed    


  71. HELOU V, Abdul-Rahman NH, Loo SK, Gao SJ, et al
    Circulating tumor DNA in Non-Viral head and neck squamous cell Carcinoma: A systematic review and Meta-Analysis.
    Oral Oncol. 2025;170:107760.
    PubMed     Abstract available


  72. WANG Q, Yang Q, Wang Z, Duan X, et al
    Efficacy of primary lesion re-irradiation in nasopharyngeal carcinoma with synchronous recurrence and distant metastasis.
    Oral Oncol. 2025;170:107743.
    PubMed     Abstract available


  73. KANG SK, Brooks E, Wolk R, Siriruchatanon M, et al
    Assessing liquid biopsy tests for the detection of head and neck squamous cell carcinoma: an umbrella review.
    Oral Oncol. 2025;170:107535.
    PubMed     Abstract available


  74. BOIDE A, Glasmacher AR, Wurschi G, Tews AM, et al
    Fear of cancer recurrence in adults with p16-positive head and neck cancer after radiotherapy - Results from a multicenter cross-sectional observational study.
    Oral Oncol. 2025;170:107757.
    PubMed     Abstract available


  75. HONG MH, Lee S, Kim CG, Son W, et al
    A phase II clinical trial of paclitaxel-carboplatin as neoadjuvant therapy followed by surgery in patients with locally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107745.
    PubMed     Abstract available


  76. JEYARAJ G
    Commentary on "Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma".
    Oral Oncol. 2025 Oct 10:107741. doi: 10.1016/j.oraloncology.2025.107741.
    PubMed    


  77. MARUDHUPANDI T
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;170:107746.
    PubMed     Abstract available


  78. LI Y, Tong S, Tian J, You X, et al
    Comment on: "Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial".
    Oral Oncol. 2025;170:107729.
    PubMed    


  79. LI S, Garb BF, Qin T, Soppe SE, et al
    Tumor subtype classification tool for HPV-associated head and neck cancers.
    Oral Oncol. 2025;170:107726.
    PubMed     Abstract available


  80. SWAIN M, Ghosh-Laskar S, McDowell L, Henson C, et al
    Patterns of care in de-novo oligo-metastatic and oligo-recurrent head and neck cancers: A Head and Neck Cancer International Group (HNCIG) Survey.
    Oral Oncol. 2025;170:107647.
    PubMed     Abstract available


  81. VARETA JA, Zhang X, Kuhnell D, Hagen MC, et al
    Characterizing the mutational landscape of sinonasal squamous cell carcinoma using whole-exome sequencing.
    Oral Oncol. 2025;169:107694.
    PubMed     Abstract available


  82. HAGREN A, Sjovall J, Brogardh C, Johansson K, et al
    Head and neck lymphedema after radiotherapy - Prevalence, changes and associated factors - a prospective observational cohort study.
    Oral Oncol. 2025;169:107671.
    PubMed     Abstract available


  83. HINTZE JM, Cleere E, Timon C, Kinsella J, et al
    The lymph node ratio is a prognostic factor for survival in laryngeal and hypopharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107625.
    PubMed     Abstract available


  84. SIQUEIRA JM, Heguedusch D, Cunha MT, de Sousa LG, et al
    Exploring TROP2 expression in oropharyngeal squamous cell carcinoma: Association with prognosis and tumor immune microenvironment composition.
    Oral Oncol. 2025;169:107634.
    PubMed     Abstract available


  85. HOUCINE Y, Kedous S, Kamoun S, Methnani A, et al
    Nasopharyngeal low-grade papillary Adenocarcinoma: A rare entity with diagnostic challenges.
    Oral Oncol. 2025;169:107612.
    PubMed     Abstract available


  86. KUMARAGURU S, Pandiyan R
    Letter to the Editor: Clinical significance of HPV16 in oropharyngeal cancer: a commentary on recent evidence.
    Oral Oncol. 2025;169:107550.
    PubMed     Abstract available


  87. MARUDHUPANDI T
    Letter to the Editor: Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
    Oral Oncol. 2025;170:107731.
    PubMed     Abstract available


  88. MARUDHUPANDI T
    Letter to the editor: Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107730.
    PubMed     Abstract available


    September 2025
  89. MISRA SR, Das R
    Palliative care integration in head and neck Cancer: Bridging the gap between evidence and practice.
    Oral Oncol. 2025;170:107735.
    PubMed    


  90. MISRA SR, Das R, Giri M
    Commentary on "pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial".
    Oral Oncol. 2025;170:107701.
    PubMed    


  91. ANNAMALAI A
    Comments on, "Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study".
    Oral Oncol. 2025;170:107716.
    PubMed    


  92. ZHANG M
    Comment on "Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma".
    Oral Oncol. 2025;170:107722.
    PubMed    


  93. HUANG S, Liao D, Zhu X, Feng Y, et al
    Advancing oral cancer equity in India novel pathways for screening impact.
    Oral Oncol. 2025;170:107696.
    PubMed    


  94. LI M, Zhou Y, Cai M
    Letter to the Editor: Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107725.
    PubMed    


  95. MISRA SR, Das R
    Esophageal dysmotility in head and neck cancer survivors: a critical step forward and the path ahead!
    Oral Oncol. 2025;170:107718.
    PubMed    


  96. DUAN Y
    Comments on: Stroke risk after head and neck cancer diagnosis and treatment in a real-world clinical cohort.
    Oral Oncol. 2025;170:107717.
    PubMed    


  97. AL MAQRASHI ZAA, Kartolo A, Meyers BM
    Resectable locally advanced head and neck squamous cell carcinoma: cut first or immune checkpoint inhibitors first?
    Oral Oncol. 2025;170:107704.
    PubMed    


  98. CHENG H, Jiang M, Kim S, Moshiri A, et al
    Uncovering chromatin factor landscapes in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;170:107687.
    PubMed     Abstract available


  99. MISRA SR, Das R
    Financial instability, insurance, and transportation barriers in oral cancer care: contrasting perspectives between the United States and India.
    Oral Oncol. 2025;169:107692.
    PubMed    


  100. SAMUEL M
    Disparities in oral cancer screening in India: reflections on NFHS 5 evidence and pathways forward.
    Oral Oncol. 2025;169:107693.
    PubMed     Abstract available


  101. SINDYA J, Rajanathadurai J, Perumal E
    Reflections on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025;169:107691.
    PubMed    


  102. SASIKALA S, Sowmiya A, Usharani N
    Letter to the Editor: Salivary DNA methylation derived estimates of biological Aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2025;169:107668.
    PubMed    


  103. LUO L, Lu C, Feng H
    Refining SCCUP management: towards safe de-escalation in HPV-positive head and neck cancer-letter on Barrett et al.
    Oral Oncol. 2025;169:107681.
    PubMed    


  104. VENKATACHALAM DK, Kanimozhi K
    Letter to the Editor "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025;169:107679.
    PubMed    


  105. MISRA SR, Das R
    The imperative of careful selection and novel strategies: Comment on Mrosk et al.'s outcomes of primary chemoradiation for advanced oral cancer.
    Oral Oncol. 2025;169:107676.
    PubMed    


  106. LOVETT JT, Westra WH, Roof S, Bakst RL, et al
    Incidence and outcomes of radiation-associated second primary malignancies in HPV-positive oropharyngeal cancer: long-term follow-up of the quarterback de-escalation trials.
    Oral Oncol. 2025;169:107654.
    PubMed     Abstract available


  107. KUMAR GN, Sangeetha S
    Comment on "Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients".
    Oral Oncol. 2025 Sep 8:107666. doi: 10.1016/j.oraloncology.2025.107666.
    PubMed    


  108. XIAO X, Liu T, Song Y, Lu M, et al
    Evaluation on the prognostic significance of cervical occult metastasis in cN0 glottic laryngeal cancer.
    Oral Oncol. 2025;169:107648.
    PubMed    


  109. ZHANG D, Zhang J, Cai M
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107660.
    PubMed    


  110. ZHANG D, Zhang P, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107661.
    PubMed    


  111. DUAN Y
    Letter to the Editor: Oral cancer screening in India: A secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107657.
    PubMed    


  112. ZHANG D, Zhou Y, Cai M
    Letter to the Editor: Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107659.
    PubMed    


  113. MISRA SR, Das R
    Critical appraisal of "Oral cancer screening in India: A secondary analysis of disparities using national family health survey data".
    Oral Oncol. 2025;169:107653.
    PubMed    


  114. PENG X, Xie Y, Liu Y
    Comment on "Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics".
    Oral Oncol. 2025;169:107644.
    PubMed    


  115. BATOOL S, Hansen EE, Sethi RKV, Rettig EM, et al
    Financial instability, insurance, and transportation influence timely head and neck cancer care in the United States: Patient and healthcare worker perspectives.
    Oral Oncol. 2025;169:107607.
    PubMed     Abstract available


  116. DUNN LA, Ho AL, Michel LS, Wong W, et al
    A phase 1/1b study of lenvatinib and cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2025;169:107524.
    PubMed     Abstract available


  117. NOEL CW, Birkenbeuel J, Ozer E, Agrawal A, et al
    Patterns of referral and outcomes in oropharyngeal cancer management.
    Oral Oncol. 2025;168:107602.
    PubMed     Abstract available


  118. GILI R, Morbini P, Bossi P
    PD-L1 Expression in head and neck squamous cell carcinoma: qualitative or quantitative assessment? Is that enough or we need something more?
    Oral Oncol. 2025;168:107606.
    PubMed     Abstract available


  119. YANG J, Wu W, Liu J, Li J, et al
    Comprehensive integration of single-cell and bulk transcriptome to reveal plasma cell heterogeneity and a prognosis signature in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;168:107595.
    PubMed     Abstract available


  120. KLEEBAYOON A, Wiwanitkit V
    Semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD): correspondence.
    Oral Oncol. 2025;169:107645.
    PubMed    


  121. BHAGIA P, Mukherjee A, Agarwal T, Giri S, et al
    Stroke risk after head and neck cancer diagnosis and treatment in a Real-World clinical cohort: Running title: Treatment in a Real-World clinical cohort.
    Oral Oncol. 2025;169:107599.
    PubMed     Abstract available


    August 2025
  122. BARRETT TF, Apicelli AJ, Ramadan S, Pipkorn P, et al
    Management of HPV+ head and neck squamous cell carcinoma with unknown primary in the era of treatment de-escalation.
    Oral Oncol. 2025;169:107631.
    PubMed     Abstract available


  123. ANSARI E, Carrillo Minulina N, van Es RJJ, Dieleman FJ, et al
    Low skeletal muscle mass and not systemic inflammation is associated with complications after free forearm flap reconstruction in oral cancer patients.
    Oral Oncol. 2025;169:107628.
    PubMed     Abstract available


  124. DAI Y, Li W
    Comment on "Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD)" by Schroter et al.
    Oral Oncol. 2025;169:107640.
    PubMed    


  125. KANA L, Chamma B, Robinette N, Cramer JD, et al
    Pre-treatment PET/CT for head and neck squamous cell carcinoma: secondary analysis of a clinical trial.
    Oral Oncol. 2025;169:107633.
    PubMed     Abstract available


  126. HUANG J, Yan X, Wang S, Huang S, et al
    Improvements to the LEF Self-Management study for head and neck cancer survivors - Letter on Deng et al.
    Oral Oncol. 2025;169:107639.
    PubMed    


  127. CAO J, Han W, Liu Y
    Letter to the editor: effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;169:107624.
    PubMed    


  128. HUANG X, Gu X
    Comment on Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;169:107626.
    PubMed    


  129. MISRA SR, Das R
    Insights on: "Social health at 5 years after diagnosis in head and neck cancer Survivors".
    Oral Oncol. 2025;169:107637.
    PubMed    


  130. BOSSI P, Kiyota N, Mesia R, Rosenberg AJ, et al
    Adverse event profiles and management of cisplatin-based chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2025;169:107596.
    PubMed     Abstract available


  131. TANG Y, Jin Q, Gan X
    Comment on "Social health at 5 years after diagnosis of head and neck cancer".
    Oral Oncol. 2025;169:107627.
    PubMed    


  132. RAHMAN R, Sheikh I, Merchant Y, Mathur A, et al
    Oral cancer screening in India: a secondary analysis of disparities using national family health survey data.
    Oral Oncol. 2025;169:107632.
    PubMed     Abstract available


  133. DAI Y, Li WJ
    Comment on "Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: A pilot randomized controlled trial" by Deng J et al.
    Oral Oncol. 2025;169:107613.
    PubMed    


  134. CHEN Y, Yan Y
    Comment on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
    Oral Oncol. 2025;169:107614.
    PubMed    


  135. LUO R, Wu J, Zhong W, Ai K, et al
    Letter to the editor - Commentary on "A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus".
    Oral Oncol. 2025;169:107610.
    PubMed    


  136. ZHANG J, Liu DM
    Advancing self-management for head and neck cancer-related lymphedema: A promising step forward.
    Oral Oncol. 2025;169:107611.
    PubMed     Abstract available


  137. SCHROTER P, Christ LV, Dvornikovich K, Stritzke F, et al
    Randomized controlled trial of semi-individualized 3D-printed tissue retraction devices vs. standard shielding splints in head and neck cancer treated with intensity-modulated and particle radiotherapy (GUARD).
    Oral Oncol. 2025;169:107604.
    PubMed     Abstract available


  138. TANG M, Dougherty M, Worona L, Ramos E, et al
    Predictive value of circulating tumor tissue-modified HPV DNA kinetics in induction therapy for oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;169:107608.
    PubMed     Abstract available


  139. COLAK G, Demir B
    Letter to the Editor: "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
    Oral Oncol. 2025;168:107579.
    PubMed    


  140. TOSONI A, Di Nunno V, Carlini A, Gatto L, et al
    The role of systemic therapy in patients with recurrent or metastatic head and neck squamous cell carcinoma progressed to immunotherapy: A systematic review and meta analysis.
    Oral Oncol. 2025;168:107582.
    PubMed     Abstract available


  141. ASHOK A, Dimitri S, Plonowska-Hirschfeld K, Wu MP, et al
    Establishing an integrated approach to head and neck cancer treatment and prevention: The Robert Ebert and Greg Stubblefield Head and Neck Tumor Center Model.
    Oral Oncol. 2025;168:107591.
    PubMed     Abstract available


  142. LAVANYA K, Sathishkumar K, Nallusamy D
    Letter to the editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107590.
    PubMed    


  143. HONGO T, Hirano Y, Tarutani Y, Omori H, et al
    Prospective study of algorithm-based chemoradioselection to optimize treatment intensity for advanced head and neck cancer.
    Oral Oncol. 2025;168:107585.
    PubMed     Abstract available


  144. KOKER G, Ozcelik G
    Comment on: "Cisplatin ototoxicity and hydration schedules''.
    Oral Oncol. 2025;168:107545.
    PubMed    


  145. DENG J, Murphy BA, Andersen LP, McMenamin E, et al
    Feasibility and preliminary efficacy of a lymphedema and fibrosis self-management program for head and neck cancer survivors: a pilot randomized controlled trial.
    Oral Oncol. 2025;168:107556.
    PubMed     Abstract available


  146. SUDARSON J
    Commentary on "molecular features of T and N stage progression in laryngeal cancer".
    Oral Oncol. 2025;168:107587.
    PubMed     Abstract available


  147. YU Z, Zhuang Z, Zhao X, Chi H, et al
    Advancing AI-driven pathology in oral cancer: opportunities for enhanced TIL assessment and clinical integration.
    Oral Oncol. 2025;168:107586.
    PubMed    


  148. ASHOKKUMAR K
    Letter to the editor - a preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107580.
    PubMed    


  149. KRISHNAN M, Jothishanmugam A, Mari A, Babu S, et al
    Preserving the mandible, protecting the patient: A commentary on fracture risk following marginal mandibulectomy in head and neck cancer.
    Oral Oncol. 2025;168:107575.
    PubMed    


  150. MATSUDA Y, Fujioka-Kobayashi M, Tatsumi H, Osako-Sonoyama R, et al
    Factors associated with postoperative oral dysfunction in patients with oral cancer: a structural equation modeling study.
    Oral Oncol. 2025;168:107577.
    PubMed     Abstract available


  151. MULARONI F, Marchi F, Gaudioso P, Taboni S, et al
    Selected laryngeal squamous cell carcinomas with laryngeal mobility impairment are suitable for curative larynx-preservation treatment: A multi-institutional study on 406 patients from the ARYFIX collaborative group.
    Oral Oncol. 2025;167:107466.
    PubMed     Abstract available


  152. MORES AL, Lima de Araujo CA, de Freitas Busnardo F, Cardili L, et al
    Cutaneous metastasis of oropharyngeal squamous cell carcinoma: A case report.
    Oral Oncol. 2025;167:107438.
    PubMed     Abstract available


  153. SEDASSARI BT, Celin MF, Pigatti FM
    SMARCB1-deficient sinonasal carcinoma with oral involvement: A potential mimicker of salivary-type carcinomas.
    Oral Oncol. 2025;167:107435.
    PubMed     Abstract available


  154. TONSBEEK AM, Hundepool CA, van der Oest M, Offerman MPJ, et al
    Life following total laryngectomy: mixed-model analyses of longitudinal patient-reported outcomes in a prospective cohort.
    Oral Oncol. 2025;167:107431.
    PubMed     Abstract available


  155. PERYASSU BC, Nicolau-Neto P, da Costa EWE, Santos IC, et al
    Assessing the prognostic significance and predictive features of cervical occult metastasis in glottic laryngeal squamous cell carcinoma.
    Oral Oncol. 2025;167:107429.
    PubMed     Abstract available


  156. DOLL C, Hofmann E, Trelinska-Finger A, Heiland M, et al
    Benefit from adjuvant radiotherapy in early-stage oral cavity and oropharyngeal cancer with solitary ipsilateral lymph node metastasis - A population-based study on German cancer registry data.
    Oral Oncol. 2025;167:107384.
    PubMed     Abstract available


  157. GUZZO M, Bianchi R, Colombo S, Santamato F, et al
    Mandibular swing approach: 25 years of experience at Istituto Nazionale Tumori of Milan.
    Oral Oncol. 2025;167:107405.
    PubMed     Abstract available


  158. TONG JY, Brimanson K, Moyer K, Wolf J, et al
    Margin analysis of radical tonsillectomy specimens following transoral robotic surgery.
    Oral Oncol. 2025;167:107403.
    PubMed     Abstract available


  159. LUNA-ORTIZ K, Guillen-Hernandez GA, Cano-Valdez AM, Alvarez-Avitia MA, et al
    Poorly differentiated ceruminous adenocarcinoma of the external auditory canal: Letter to the editor.
    Oral Oncol. 2025;168:107544.
    PubMed    


  160. JENNIFER LG, Larnaudie A, Bene MC, Cocherie T, et al
    Relationships between oral microbiome and head and neck squamous cell carcinoma: a systematic review.
    Oral Oncol. 2025;168:107571.
    PubMed     Abstract available


  161. HUMBERT M, Perreard M, Licaj I, Bouhnik AD, et al
    Social health at 5 years after diagnosis of head and neck cancer.
    Oral Oncol. 2025;168:107567.
    PubMed     Abstract available


    July 2025
  162. ELIA A, Tirosh O, Dinstag G, Gugel L, et al
    Prediction of clinical outcomes of immune checkpoint inhibitors in advanced head and neck cancer directly from histopathology slides using inferred transcriptomics.
    Oral Oncol. 2025;168:107536.
    PubMed     Abstract available


  163. LI Y, Xiao L, Xie R
    Mitigating survival disparities in head and neck cancer: urgent need to reduce ED-based biopsy delays.
    Oral Oncol. 2025;168:107549.
    PubMed    


  164. SHARFUNNISA SH
    Letter to the editor "reframing nutritional support in head and neck cancer: insights from a prospective cohort study".
    Oral Oncol. 2025;168:107563.
    PubMed    


  165. ZHANG D, Cai M
    Letter to the Editor: A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107558.
    PubMed    


  166. RAJASEKAR A
    Letter to the Editor: HCV infection in head and neck cancer patients: Implications for screening and prognosis in a low prevalence setting.
    Oral Oncol. 2025;168:107561.
    PubMed     Abstract available


  167. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Corrigendum to "Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas". [Oral Oncol. 163 (2025) 107207].
    Oral Oncol. 2025 Jul 27:107510. doi: 10.1016/j.oraloncology.2025.107510.
    PubMed    


  168. KRISHNAN M, Babu S
    Commentary on Lee et al: From crisis to diagnosis: redefining the emergency department's role in head and neck cancer detection.
    Oral Oncol. 2025;168:107546.
    PubMed    


  169. PENG J, Liang Z, Wang J, Wang G, et al
    Comment on effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;168:107537.
    PubMed    


  170. KRISHNAN M, Babu S
    Letter to the editor: redefining surgical paradigms in isthmic papillary thyroid carcinoma: a timely reappraisal.
    Oral Oncol. 2025;168:107562.
    PubMed    


  171. NARENKUMAR J, Parthipan P
    Letter to the Editor: Impact of the COVID-19 pandemic on diagnosis and disease stage in HPV-positive oropharyngeal cancer: insights and future directions.
    Oral Oncol. 2025;168:107541.
    PubMed     Abstract available


  172. D'ANDREA C, Marhic A, Leveque E, Thureau S, et al
    Risk factors for fractures after marginal mandibulectomy for head and neck cancer multicentre study.
    Oral Oncol. 2025;168:107512.
    PubMed     Abstract available


  173. BABU S, Krishnan M, Ravi PS
    "Commentary on: Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction".
    Oral Oncol. 2025;168:107552.
    PubMed    


  174. KRISHNAN M, Chawla KK, Babu S, D S, et al
    Letter to the editor: Molecular stratification in papillary thyroid carcinoma: Should RET fusions redefine aggressiveness in the post-BRAF era?
    Oral Oncol. 2025;168:107543.
    PubMed    


  175. MORCOM CR, Williams CMD, Al-Qadami G, Vieyra CP, et al
    The biological mechanisms underpinning nutritional and health-related consequences of mucositis in head and neck cancer - A review.
    Oral Oncol. 2025;168:107548.
    PubMed    


  176. ARULMOORTHY MP
    Navigating the diagnostic delay: optimizing timely biopsy and integrating NIR-based technologies for head and neck cancer.
    Oral Oncol. 2025;168:107518.
    PubMed     Abstract available


  177. SHARFUNNISA SH, Rahmathullah A
    Letter to the editor "Integrating nutritional profiling into immunotherapy: A modifiable predictor of outcomes in head and neck Cancer".
    Oral Oncol. 2025;168:107539.
    PubMed    


  178. BABU S, Solomon A, Krishnan M
    Commentary on "Massive nasal bleeding in nasopharyngeal carcinoma: Incidence, risk predictors, and survival impact".
    Oral Oncol. 2025;168:107528.
    PubMed    


  179. JEYARAJ G
    Commentary on, "Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department".
    Oral Oncol. 2025;168:107532.
    PubMed    


  180. ABILAJI S, Parthipan P
    Letter to the Editor: Evaluating the risk-modifying effects of HSV-1 and HSV-2 on head and neck cancer in relation to tobacco, alcohol, and HPV-16.
    Oral Oncol. 2025;168:107516.
    PubMed     Abstract available


  181. CHAWLA JPS, Madan GK
    Comment on "Current status of circulating tumour DNA and circulating cell alterations in HPV-associated head and neck cancer".
    Oral Oncol. 2025;168:107526.
    PubMed    


  182. ZHU J, Xu J, Qu H, Hao J, et al
    A preliminary exploration of surgical strategies for solitary papillary thyroid carcinoma on the isthmus.
    Oral Oncol. 2025;168:107511.
    PubMed     Abstract available


  183. LEE MY, Huynh JD, Kim DD, Sunwoo JB, et al
    Effects of diagnostic delays in head and neck cancer patients presenting to the emergency department.
    Oral Oncol. 2025;168:107467.
    PubMed     Abstract available


  184. YANG Z, Lin B, Xie R
    Microvascular tongue reconstruction in oral cancer: Long-term functional outcomes and quality of life considerations.
    Oral Oncol. 2025;167:107490.
    PubMed    


  185. ZHANG Y, Liang R, Lai P
    Comment on "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
    Oral Oncol. 2025;167:107491.
    PubMed    


  186. JEYARAJ G
    Commentary on, "Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: Surgical and oncological outcomes.".
    Oral Oncol. 2025;167:107487.
    PubMed    


  187. RAJATHIRAJAN SD
    Commentary on, "Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study".
    Oral Oncol. 2025;167:107483.
    PubMed    


  188. JEYARAJ G
    Commentary on, "Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact.".
    Oral Oncol. 2025;167:107488.
    PubMed    


  189. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
    Corrigendum to "Massive nasal bleeding in nasopharyngeal carcinoma: incidence, risk predictors, and survival impact" [Oral Oncol. 167 (2025) 107456].
    Oral Oncol. 2025 Jul 4:107465. doi: 10.1016/j.oraloncology.2025.107465.
    PubMed    


  190. RAJATHIRAJAN SD
    Commentary on, "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors".
    Oral Oncol. 2025;167:107472.
    PubMed    


  191. HU A, Wen X, Tian J, Wang Z, et al
    RET fusion rather than BRAF mutation confers a higher risk of aggressiveness and recurrence in papillary thyroid carcinoma.
    Oral Oncol. 2025;167:107464.
    PubMed     Abstract available


  192. RIJKEN JA, de Ridder M, Devriese LA, Breimer GE, et al
    Long-term survival after multimodal treatment of sinonasal NUT carcinoma: a case report.
    Oral Oncol. 2025;166:107392.
    PubMed     Abstract available


  193. RONDI P, Mattavelli D, Rampinelli V, Schreiber A, et al
    The role of volumetry in sinonasal cancer response assessment to induction chemotherapy, results from two phase II non-randomized controlled prospective multicentric trials: SINTART-1 and SINTART-2.
    Oral Oncol. 2025;166:107388.
    PubMed     Abstract available


  194. SOMAY E, Bascil S, Topkan E, Selek U, et al
    Re: "Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors" by Kamel et al.
    Oral Oncol. 2025;167:107457.
    PubMed    


    June 2025
  195. MALGAVE DS, Hartman CM, Kramer JR, Richardson PA, et al
    Impact of HIV status on overall survival in head and neck cancers by anatomical site and stage: A multi-center cohort study.
    Oral Oncol. 2025;167:107446.
    PubMed     Abstract available


  196. ABILAJI S, Narenkumar J
    Letter to the Editor: Enhancing early detection of HPV associated oropharyngeal cancer: a comparative study of NGS, ddPCR, and qPCR.
    Oral Oncol. 2025 Jun 27:107461. doi: 10.1016/j.oraloncology.2025.107461.
    PubMed     Abstract available


  197. EICKELSCHULTE S, Starus A, Murray DH, Keyser KA, et al
    Analytical and clinical performance validation of HPV-SEQ, a novel NGS-based liquid biopsy platform for detection and quantification of human papilloma virus circulating tumor DNA.
    Oral Oncol. 2025;167:107445.
    PubMed     Abstract available


  198. RAJATHIRAJAN SD
    Commentary on, "Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging".
    Oral Oncol. 2025;167:107453.
    PubMed    


  199. CHENG HS, Lin TY, Twu CW, Lin PJ, et al
    Massive nasal bleeding in nasopharyngeal Carcinoma: Incidence, risk Predictors, and survival impact: Running title: Massive nasal bleeding in NPC.
    Oral Oncol. 2025;167:107456.
    PubMed     Abstract available


  200. DAUNGSUPAWONG H, Wiwanitkit V
    Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: Comment.
    Oral Oncol. 2025;167:107454.
    PubMed    


  201. SAMUEL CHAN SW, Amer Al Maqrashi ZA, Kim DH, Choi D, et al
    Induction chemotherapy and immunotherapy followed by chemo-radiotherapy in incurable advanced head and neck squamous cell carcinoma: A case-series.
    Oral Oncol. 2025;167:107439.
    PubMed    


  202. NGO DQ, Truong DS, Le DT, Hoang TM, et al
    Transoral endoscopic thyroidectomy vestibular approach for pT1b papillary thyroid carcinoma: surgical and oncological outcomes.
    Oral Oncol. 2025;167:107406.
    PubMed     Abstract available


  203. ARAUJO M, Bouassaly J, Farshadi F, Hier M, et al
    Current status of circulating tumor DNA and circulating cell alterations in HPV-associated head and neck cancer.
    Oral Oncol. 2025;167:107417.
    PubMed     Abstract available


  204. KAMEL S, Humbert-Vidan L, Kaffey Z, Mirbahaeddin S, et al
    Computed tomography radiomics-based cross-sectional detection of mandibular osteoradionecrosis in head and neck cancer survivors.
    Oral Oncol. 2025;167:107337.
    PubMed     Abstract available


  205. MAK CH, Cao LM, Luo HY, Zhou K, et al
    Postoperative complications of neck dissection for head and neck squamous cell carcinoma: a systematic review and meta-analysis.
    Oral Oncol. 2025;167:107430.
    PubMed     Abstract available


  206. YANG X, Li R
    Reconsidering the prognostic value of HRQOL in head and neck cancer.
    Oral Oncol. 2025;167:107421.
    PubMed    


  207. YAN Y, Wang Z, Sun Y
    Comment on: Margins do not impact recurrence and survival in advanced laryngeal cancer-A retrospective cohort analysis.
    Oral Oncol. 2025;167:107427.
    PubMed    


  208. LIANG YJ, Luo MJ, Wen DX, Wang P, et al
    Optimal induction chemotherapy courses in nasopharyngeal carcinoma in the IMRT era: A recursive partitioning risk stratification analysis based on EBV DNA and AJCC staging.
    Oral Oncol. 2025;167:107404.
    PubMed     Abstract available


  209. KIM MJ, Koo BS, Cho KJ, Lee SH, et al
    Health-related quality-of-life assessment in patients with oropharyngeal cancer: A comparison of EQ-5D-5L and EORTC instruments.
    Oral Oncol. 2025;165:107342.
    PubMed     Abstract available


  210. GARSET-ZAMANI M, Makouei F, Agander TK, Lelkaitis G, et al
    Feasibility of 3D ultrasound for intraoperative tumor margin assessment in transoral robotic surgery for oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;165:107330.
    PubMed     Abstract available


  211. KUMARI S, Mishra S, Ali W, Singh US, et al
    Implication of circulating miRNAs as potential diagnostic biomarker in oropharyngeal squamous cell Carcinoma: Association with Human Papilloma Virus.
    Oral Oncol. 2025;165:107305.
    PubMed     Abstract available


  212. JANG HB, Lee DH, Lim SC
    Treatment outcomes of sinonasal adenoid cystic carcinoma: a single-center experience.
    Oral Oncol. 2025;165:107317.
    PubMed     Abstract available


  213. CHELVARAJAH RC, Liu Y, Su J, Abdalaty AH, et al
    Factors associated with detection of oligometastatic recurrence and outcome following definitive (Chemo)radiotherapy for oropharyngeal carcinoma.
    Oral Oncol. 2025;165:107310.
    PubMed     Abstract available


    May 2025
  214. HINTZE JM, Cleere E, Soo A, Timon C, et al
    Margins do not impact recurrence and survival in advanced laryngeal cancer - A retrospective cohort analysis.
    Oral Oncol. 2025;167:107402.
    PubMed     Abstract available


  215. BAIJU DC, Ravi J, Sarma M, Sureshan M, et al
    Detection of hotspot mutations in oral cancer through Ion AmpliSeq cancer hotspot panel v.2.0: A circulating DNA fragmentomics approach in the Northeast Indian population.
    Oral Oncol. 2025;166:107387.
    PubMed     Abstract available


  216. JEYARAJ G
    Commentary on, "The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study".
    Oral Oncol. 2025;166:107401.
    PubMed    


  217. LIU X, Xue S
    Comment on: Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2025;166:107368.
    PubMed    


  218. VERDONCK-DE LEEUW IM, Lissenberg-Witte BI, de Bree R, Buffart LM, et al
    The association between health-related quality of life and five-year overall survival among head and neck cancer patients: A prospective cohort study.
    Oral Oncol. 2025;166:107367.
    PubMed     Abstract available


  219. OLSON B, Bogan A, Abdel-Halim CN, Rolle-McFarland D, et al
    Identification of clinical and pathologic features associated with extranodal extension in patients with HPV-mediated oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;166:107308.
    PubMed     Abstract available


  220. TONSBEEK AM, van der Lely JN, Bulstra L, Venema J, et al
    Long-term health-related quality of life in oral cancer survivors following microvascular tongue reconstruction.
    Oral Oncol. 2025;166:107363.
    PubMed     Abstract available


  221. MALI SB
    Corrigendum to "Review of STAT3 (Signal Transducers and Activators of Transcription) in head and neck cancer" [Oral Oncol. 51 (2015) 565-569].
    Oral Oncol. 2025 May 10:107357. doi: 10.1016/j.oraloncology.2025.107357.
    PubMed    


  222. MALI SB
    Corrigendum to "RNA interference in oral cancer" [Oral Oncol. 51 (2015) e2-e3].
    Oral Oncol. 2025 May 9:107358. doi: 10.1016/j.oraloncology.2025.107358.
    PubMed    


  223. SHAIKH N, Pandey M, Manna S, Gawde J, et al
    Evaluating the prognostic value of tumor-derived circulating endothelial cells and their progenitors in platinum-refractory oral cancer patients for response to triple metronomic therapy.
    Oral Oncol. 2025;165:107346.
    PubMed     Abstract available


  224. COSTANTINO A, Haughey BH, Alamoudi U, Magnuson JS, et al
    Prognostic significance of distant metastasis site at diagnosis in HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107361.
    PubMed     Abstract available


  225. ONAGA R, Enokida T, Kuno H, Hiyama T, et al
    Significance of imaging-detected extranodal extension in locally advanced squamous cell carcinoma of the head and neck treated with induction chemotherapy followed by chemoradiotherapy.
    Oral Oncol. 2025;165:107351.
    PubMed     Abstract available


  226. ZHU X, Xu H, Zhao Y, Diao W, et al
    Single-cell transcriptomics reveal the effects of chemoimmunotherapy on hypopharyngeal cancer and its tumor microenvironment.
    Oral Oncol. 2025;165:107347.
    PubMed     Abstract available


  227. PEI Y, Yang Z, Mao Y, Chen X, et al
    Evolving dynamics in clinical trials for oral cancer: Trends, treatment modalities, and future directions.
    Oral Oncol. 2025;165:107333.
    PubMed     Abstract available


  228. XIAO X, Liu T, Lu M, Song Z, et al
    Comment on the role of lymph node level ratio in predicting prognosis of pN1 head and neck squamous cell carcinoma.
    Oral Oncol. 2025;165:107344.
    PubMed    


  229. CHENNAREDDY S, Chen S, Levinson C, Genden EM, et al
    Circulating tumor DNA in human papillomavirus-associated oropharyngeal cancer management: A systematic review.
    Oral Oncol. 2025;164:107262.
    PubMed     Abstract available


  230. MARCHI F, Del Bon F, Chu F, Sampieri C, et al
    Refining prognostic subcategories in intermediate-advanced glottic cancer: A multicentric study on 637 patients treated by transoral laser microsurgery.
    Oral Oncol. 2025;164:107264.
    PubMed     Abstract available


  231. CANALI L, Russo E, Pangallo S, Bussu F, et al
    Regional disease control in nasal vestibule squamous cell carcinoma: Systematic review and meta-analysis.
    Oral Oncol. 2025;164:107270.
    PubMed     Abstract available


  232. MOTTA G, Magno C, Castagna L, De Berardinis T, et al
    Endoscope-assisted trans-oral approach (EATA) to remove a rare pleomorphic adenoma of the nasopharynx.
    Oral Oncol. 2025;164:107260.
    PubMed     Abstract available


  233. BEDDOK A, Popovtzer A, Calugaru V, Fontaine M, et al
    Proton therapy for primary and recurrent HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107309.
    PubMed     Abstract available


    April 2025
  234. MALI SB
    Corrigendum to "Proteomics for oral cancer" [Oral Oncol. 50(11) (2014) e67].
    Oral Oncol. 2025 Apr 30:107338. doi: 10.1016/j.oraloncology.2025.107338.
    PubMed    


  235. CITRO S, Ghiani L, Doni M, Miccolo C, et al
    HPV-mediated PARP1 regulation and drug sensitization in head and neck cancer.
    Oral Oncol. 2025;165:107307.
    PubMed     Abstract available


  236. SILVA CUNHA JL
    Comment on "Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma".
    Oral Oncol. 2025;165:107336.
    PubMed    


  237. AL FADEL AM, Jakobsen KK, Jensen LH, Carlander AF, et al
    The epidemiological trends and survival of HPV-related oropharyngeal cancer other than tonsils and base of tongue - a systematic review and meta-analysis.
    Oral Oncol. 2025;165:107311.
    PubMed     Abstract available


  238. ARDILA CM
    Enhancing the scope and impact of photobiomodulation research in head and neck cancer therapy.
    Oral Oncol. 2025;165:107303.
    PubMed    


  239. JEYARAJ G
    Commentary on, "Molecular features of T and N stage progression in laryngeal cancer.".
    Oral Oncol. 2025;165:107331.
    PubMed    


  240. BARCELONA MVN, Waldron J, Sullivan BO, Su J, et al
    Outcomes following IMRT alone in head and neck squamous cell carcinoma ordinarily managed with concurrent chemo-radiotherapy.
    Oral Oncol. 2025;165:107299.
    PubMed     Abstract available


  241. YAO CMKL, Hueniken K, Huang SH, Liu G, et al
    Development of a patient reported outcomes based machine learning model to predict recurrences in head and neck cancer.
    Oral Oncol. 2025;165:107304.
    PubMed     Abstract available


  242. JEYARA G
    Commentary on, "Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.".
    Oral Oncol. 2025;165:107320.
    PubMed    


  243. ZHOU P, Zhu Y, Xu B, Jiang X, et al
    Cavernous sinus syndrome in a patient with occult nasopharyngeal carcinoma: A diagnostic challenge.
    Oral Oncol. 2025;165:107316.
    PubMed     Abstract available


  244. COSTANTINO A, Sampieri C, Haughey BH, Alamoudi U, et al
    Adjuvant treatment in elderly patients undergoing transoral surgery for HPV-related oropharyngeal cancer.
    Oral Oncol. 2025;165:107312.
    PubMed     Abstract available


  245. KOSKENNIEMI AR, Huusko T, Routila J, Jalkanen S, et al
    Histological tumor necrosis predicts decreased survival after neoadjuvant chemotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;165:107287.
    PubMed     Abstract available


  246. JEYARAJ G
    Commentary on, "Effect of Enhanced Recovery After Radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial".
    Oral Oncol. 2025;165:107302.
    PubMed    


  247. LI N, Zeng PYF, Kim HAJ, Karimi A, et al
    Molecular features of T and N stage progression in laryngeal cancer.
    Oral Oncol. 2025;165:107283.
    PubMed     Abstract available


  248. BURGER AVM, Koot MA, van Balen DEM, Schaeffers AWMA, et al
    Comparison of cisplatin-induced hearing loss in different durations of infusion and volume of hydration schedules in head and neck squamous cell carcinoma patients treated with cisplatin-based chemoradiation.
    Oral Oncol. 2025;164:107246.
    PubMed     Abstract available


  249. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].
    Oral Oncol. 2025 Apr 11:107292. doi: 10.1016/j.oraloncology.2025.107292.
    PubMed    


  250. MA J, Brooks C, Tasoulas J, Wind LS, et al
    Revisiting the use of capecitabine in the era of immunotherapy: Efficacy as second-line and later therapy in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2025;164:107293.
    PubMed    


  251. SLATER NN, Herberger L, Farsi S, Rogers AL, et al
    Assessing barriers to adjuvant therapy among patients with head and neck cancer in Arkansas.
    Oral Oncol. 2025;164:107290.
    PubMed     Abstract available


  252. XIAO J, You M, Song Y, Gao R, et al
    Risk factors and a risk assessment model for venous thromboembolism in head and neck cancer surgery.
    Oral Oncol. 2025;164:107288.
    PubMed     Abstract available


  253. VIANNA CAMOLESI GC, Prado-Pena IB, Gomez-Caamano A, Victoria-Fernandez C, et al
    Photobiomodulation for the prevention of oral side effects secondary to head and neck cancer therapy: results of a randomised, single-blind clinical trial.
    Oral Oncol. 2025;164:107266.
    PubMed     Abstract available


  254. JEYARAJ G
    Commentary on, "Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort".
    Oral Oncol. 2025;164:107285.
    PubMed    


  255. ROSING F, Plath M, Proctor T, Hofler D, et al
    Post-treatment monitoring of surgically treated oropharyngeal squamous cell carcinoma patients using human papillomavirus cell-free DNA.
    Oral Oncol. 2025;163:107225.
    PubMed     Abstract available


    March 2025
  256. LIN N, Zhou X, Wang Y, Zhou J, et al
    Effect of enhanced recovery after radiotherapy (ERAR) on the quality of life in patients with nasopharyngeal carcinoma after radiotherapy: A randomized controlled trial.
    Oral Oncol. 2025;164:107269.
    PubMed     Abstract available


  257. JEYARAJ G
    Commentary on, "Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study".
    Oral Oncol. 2025;163:107256.
    PubMed    


  258. ARDILA CM, Yadalam PK
    AI-driven histopathologic insights in HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107261.
    PubMed    


  259. MATHEW JM, Busca I, Baskurt Z, Giuliani M, et al
    Changes in unmet needs after treatment for head and neck cancers - A prospective longitudinal cohort study.
    Oral Oncol. 2025;163:107250.
    PubMed     Abstract available


  260. DONG Z, Wang GY, Qin GJ, Dai DY, et al
    Thyroid volumes after intensity-modulated radiotherapy as predictors of radiation-induced hypothyroidism in nasopharyngeal carcinoma: A retrospective study.
    Oral Oncol. 2025;163:107223.
    PubMed     Abstract available


  261. LORENZ FJ, Kharouta M, Mahase SS, Goyal N, et al
    Hospital-Based Registry Analysis of Staging Efficacy and Proposed Staging Subclassification for Stage I HPV-Associated Oropharyngeal Squamous Cell Carcinoma.
    Oral Oncol. 2025;163:107251.
    PubMed     Abstract available


  262. PETRELLI F, Lorini L, Paderno A, Carioli D, et al
    Treatment of primary tumor in metastatic head and neck Carcinoma: A systematic review and Meta-Analysis.
    Oral Oncol. 2025;163:107248.
    PubMed     Abstract available


  263. HIEROMNIMON HM, Trzcinska A, Wen FT, Howard FM, et al
    Analysis of AI foundation model features decodes the histopathologic landscape of HPV-positive head and neck squamous cell carcinomas.
    Oral Oncol. 2025;163:107207.
    PubMed     Abstract available


  264. GAZZINI L, Festa BM, Calabrese L
    Elective neck dissection: Are we bound to outdated concepts?
    Oral Oncol. 2025;163:107245.
    PubMed    


  265. WU WJ, An PG, Liu Q, Zhang ZQ, et al
    Neoadjuvant chemoimmunotherapy brings superior quality of life of patients with locally advanced oral or oropharyngeal cancer: A propensity score-matched analysis.
    Oral Oncol. 2025;162:107218.
    PubMed     Abstract available


  266. YANG F, Peng W, Wei H, Li X, et al
    Model-free parameters derived from intravoxel inherent motion combined with tumor aggressiveness indicators in predicting 5-year treatment outcome in NPC.
    Oral Oncol. 2025;162:107187.
    PubMed     Abstract available


  267. YE Z, Li X, Xie F, Sun J, et al
    A single-cell sequencing-based analysis of a 13-year-old with maxillary sinus NUT carcinoma.
    Oral Oncol. 2025;162:107185.
    PubMed     Abstract available


  268. CHARLTON A, Mughal Z, Sharin F, Sahota RB, et al
    Prevalence of synchronous bilateral/contralateral tonsil carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2025;162:107180.
    PubMed     Abstract available


  269. DE VETTE SPM, van Rijn-Dekker MI, Van den Bosch L, Keijzer K, et al
    Evaluation of a comprehensive set of normal tissue complication probability models for patients with head and neck cancer in an international cohort.
    Oral Oncol. 2025;163:107224.
    PubMed     Abstract available


  270. MIYAGUCHI J, Shiga K, Katagiri K, Saito D, et al
    Efficacy of boron neutron capture therapy (BNCT) for patients with oral cancer.
    Oral Oncol. 2025;163:107228.
    PubMed     Abstract available


    February 2025
  271. WICZUK-WICZEWSKA M, Bernaciak J, Nogal P, Bugaj A, et al
    Squamous cell carcinoma in the posterior larynx: A rare localization of supraglottic T1 laryngeal cancer. Case report.
    Oral Oncol. 2025;163:107227.
    PubMed     Abstract available


  272. JEYARAJ G
    Letter to the editor, "Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell carcinoma: A multicenter, open-label, single-arm, phase 1b study.".
    Oral Oncol. 2025;163:107231.
    PubMed    


  273. TINO RB, Roach MA, Fuentes GD, Agrawal A, et al
    Response to recent comments on "Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy".
    Oral Oncol. 2025;162:107220.
    PubMed    


  274. MEEKER BS MO, Katragadda A, Alsavaf MB, Birkenbeuel J, et al
    Dysphagia in head and neck cancer patients with evidence of esophageal dysmotility on manometry.
    Oral Oncol. 2025;162:107219.
    PubMed     Abstract available


  275. YANG H, Sun P, Wang Y, Wang X, et al
    Mitoxantrone hydrochloride liposome injection for the treatment of Recurrent/Metastatic head and neck squamous cell Carcinoma: A Multicenter, Open-label, Single-arm, phase 1b study.
    Oral Oncol. 2025;162:107211.
    PubMed     Abstract available


  276. IQBAL MS, West N, Kovarik J, Jackson M, et al
    Effective, efficient palliative radiotherapy for advanced head and neck cancer: Real world data using 25 Gy in 5 fractions.
    Oral Oncol. 2025;162:107214.
    PubMed    


  277. KHAN A, Pillay M, Bipath R, Msimang M, et al
    Evolution of testing for the diagnosis of human papillomavirus (HPV) status in head and neck squamous cell carcinoma: Where from and where to?
    Oral Oncol. 2025;162:107208.
    PubMed     Abstract available


  278. MO Y, Wei Y, Liang L, Wu T, et al
    Clinical significance of post-chemoradiotherapy 2-[(18)F]FDG PET/CT response in locally advanced nasopharyngeal carcinoma: A real-world study.
    Oral Oncol. 2025;161:107160.
    PubMed     Abstract available


  279. LOUBIERES C, Baudouin R, Circiu M, Couineau F, et al
    Functional and oncological outcomes of transoral laser versus robotic surgery in supraglottic squamous cell carcinoma.
    Oral Oncol. 2025;161:107178.
    PubMed     Abstract available


  280. PERSHAD AR, Ferraro T, Shaver TB, Lee E, et al
    Pathologic responses and clinical outcomes with neoadjuvant doublet chemotherapy for newly diagnosed, surgically-resectable p16-positive oropharyngeal cancer.
    Oral Oncol. 2025;161:107139.
    PubMed     Abstract available


  281. FENG ZK, Wu WB, Zou RC, Zhang JZ, et al
    Postradiotherapy nasopharyngeal necrosis with granulation mass: Insights from a multicentre study.
    Oral Oncol. 2025;161:107170.
    PubMed     Abstract available


  282. LYU SI, Fretter C, Eckel HNC, Knipper K, et al
    High expression of H2AX/gamma-H2AX is associated with distinct biological pathway alterations and shorter survival in oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2025;161:107171.
    PubMed     Abstract available


  283. KWON JJ, Milner TD, Kurten C, Pang EH, et al
    Towards transcervical ultrasound-guided transoral robotic surgery.
    Oral Oncol. 2025;161:107167.
    PubMed     Abstract available


  284. SUCHAN M, Wuerdemann N, Wagner S, Langer C, et al
    Histological and genetic criteria define a clinically relevant subgroup of HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2025;162:107209.
    PubMed     Abstract available


    January 2025
  285. WENGER TA, Gao J, Nurimba M, Phung PG, et al
    Palliative care utilization among head and neck cancer patients: A population-based analysis.
    Oral Oncol. 2025;162:107205.
    PubMed     Abstract available


  286. CHEN L, Fang R, Cai Z, Huang B, et al
    CD271(high) cancer stem cells regulate macrophage polarization in head and neck squamous cell carcinoma.
    Oral Oncol. 2025;162:107181.
    PubMed     Abstract available


  287. YIN Z, Zhao H, Zhu C, Fang J, et al
    Comment on: Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2025;161:107195.
    PubMed    


  288. JIANG H, Zhou L, Zhao T, Zou G, et al
    Anaplastic thyroid carcinoma in a 43-year-old female confirmed by metastatic lymph node pathology: A case report.
    Oral Oncol. 2025;161:107192.
    PubMed    


  289. JIANG H, Zhou L, Zou G, Zhang H, et al
    Synchronous papillary and medullary thyroid carcinoma with distinct genetic mutations: A case report.
    Oral Oncol. 2025;161:107191.
    PubMed    


  290. LI MH, Hu YJ, Shan HM, Gao XL, et al
    The role of lymph node level ratio in predicting prognosis and the benefits of postoperative radiotherapy in patients with pathological N1 stage head and neck squamous cell carcinoma.
    Oral Oncol. 2025;161:107193.
    PubMed     Abstract available


  291. HUTTINGER ZM, Gogineni E, Baliga S, Blakaj DM, et al
    Circulating tumor DNA determines induction chemotherapy response in HPV associated oropharyngeal squamous cell carcinoma: A pilot study.
    Oral Oncol. 2025;161:107179.
    PubMed     Abstract available


  292. TOPKAN E, Somay E, Selek U
    Commentary on "Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF".
    Oral Oncol. 2025;161:107175.
    PubMed    


  293. SENYUREK S, Durankus NK, Selek U, Topkan E, et al
    Comment on "The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2025;161:107177.
    PubMed    


  294. GIUNCO S, Del Mistro A, Morello M, Lidonnici J, et al
    From infection to immortality: The role of HPV and telomerase in head and neck cancer.
    Oral Oncol. 2025;161:107169.
    PubMed     Abstract available


  295. HANNA GJ, Zheng D, Gao W, Hair GM, et al
    PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.
    Oral Oncol. 2025;161:107146.
    PubMed     Abstract available


  296. XU S, He J, Liu Z, Pei Y, et al
    Immune-related adverse events as prognostic biomarkers in recurrent or metastatic nasopharyngeal carcinoma receiving PD-L1 inhibitor: A post-hoc analysis of the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2025;161:107161.
    PubMed     Abstract available


    December 2024
  297. KAOREY N, Dickinson K, Agnihotram VR, Zeitouni A, et al
    The role of ctDNA from liquid biopsy in predicting survival outcomes in HPV-negative head and neck cancer: A meta-analysis.
    Oral Oncol. 2024;161:107148.
    PubMed     Abstract available


  298. LIU Y, Fu N, Liu H, Su S, et al
    Corrigendum to "Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations" [160 (2025) 107120/Article:OO_107120].
    Oral Oncol. 2024 Dec 30:107135. doi: 10.1016/j.oraloncology.2024.107135.
    PubMed    


  299. DIETRICH N, Watson E, Tadic T, Martino R, et al
    Development of a prediction model for tube feeding dependence in HPV-associated oropharyngeal cancer patients undergoing chemoradiotherapy.
    Oral Oncol. 2024;161:107132.
    PubMed     Abstract available


  300. FANG Q, Yuan J, Zhang X, Dai L, et al
    Omitting elective neck dissection in cT1/2N0 oral squamous cell carcinoma with sentinel lymph node metastasis: A prospective study.
    Oral Oncol. 2024;161:107149.
    PubMed     Abstract available


  301. PRICE JM, Garcez K, Hughes C, Lee LW, et al
    The effect of time from surgery to commencing adjuvant radiotherapy for patients with head and neck squamous cell carcinoma.
    Oral Oncol. 2024;161:107138.
    PubMed     Abstract available


  302. STRUCKMEIER AK, Gosau M, Smeets R
    Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA.
    Oral Oncol. 2024;161:107145.
    PubMed     Abstract available


  303. MEGWALU UC, Ma Y, Divi V
    Association of race and ethnicity with quality of care among head and neck cancer patients in California.
    Oral Oncol. 2024;161:107144.
    PubMed     Abstract available


  304. PACE GM, Costantino A, De Virgilio A
    Comment on "Surgical, functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal cancers: A systematic review".
    Oral Oncol. 2024;161:107142.
    PubMed    


  305. YU ST, Huang D, Xiong C, Xie R, et al
    Selperctinib as neoadjuvant therapy for RET-altered papillary thyroid carcinoma: Two case reports.
    Oral Oncol. 2024;161:107140.
    PubMed     Abstract available


  306. ALMEIDA ND, Yu H, Iovoli AJ, Fang M, et al
    Prophylactic gastrostomy tube during chemoradiation for head and neck cancer decreases weight loss but increases rate of tube use beyond six months.
    Oral Oncol. 2024;160:107136.
    PubMed     Abstract available


  307. DA MOTA SANTANA LA, Dos Santos Barreto M, Santos GA, Gopalsamy RG, et al
    Comment on "Time to treatment for head and neck cancer patients decreased during the early phase of the COVID-19 pandemic".
    Oral Oncol. 2024;160:107134.
    PubMed    


  308. PRACHA SH, Shrestha S, Ryan N, Upadhaya P, et al
    Targeting macrophage migration inhibitory factor to inhibit T cell immunosuppression in the tumor microenvironment and improve cancer outcomes in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;160:107126.
    PubMed     Abstract available


  309. LI H, Lou L, Du J, Li M, et al
    Multimodal profiling uncovers tertiary lymphoid structures as a critical determinant of immunotherapy response and prognosis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;160:107129.
    PubMed     Abstract available


  310. SANKAR GANESH P, Naseef Pathoor N, Kanna Gopal R
    Letter to the editor regarding, "Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma".
    Oral Oncol. 2024;159:107091.
    PubMed     Abstract available


  311. BALAJI H, Aithal VU, Varghese JJ, Devaraja K, et al
    Agreement between patient-reported and clinician-rated speech and swallowing outcomes - Understanding the trend in post-operative oral cavity cancer patients.
    Oral Oncol. 2024;159:107068.
    PubMed     Abstract available


  312. BALAGURU L, Hanubal KS, Galochkina Z, Lee JH, et al
    Surgical and functional outcomes after salvage oropharyngectomy.
    Oral Oncol. 2024;159:107050.
    PubMed     Abstract available


  313. KORIC A, Chang CP, Hu S, Snyder J, et al
    Oral health-related quality of life among oropharyngeal cancer survivors.
    Oral Oncol. 2024;159:107062.
    PubMed     Abstract available


  314. BOZKURT G, Turri Zanoni M, Ferrari M, Ioppi A, et al
    Salvage surgery in nasopharyngeal Cancer: Unraveling the efficacy of transnasal endoscopic nasopharyngectomy for advanced stage recurrent tumors.
    Oral Oncol. 2024;159:107048.
    PubMed     Abstract available


  315. DANIELS KE, Awad DR, Liu SX, Mocharnuk J, et al
    Impact of post-operative transoral robotic surgery hemorrhage on adjuvant treatment delays in patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107031.
    PubMed     Abstract available


  316. GREEN L, McDowell L, Ip F, Tapia M, et al
    Early return to work is possible after transoral robotic surgery (TORS) in carefully selected patients with oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;159:107032.
    PubMed     Abstract available


  317. LU YT, Lin CW, Su SC, Ho YT, et al
    L48H37, a curcumin analog, suppresses matrix metalloproteinase-9 expression and activity to hamper nasopharyngeal cancer cell migration.
    Oral Oncol. 2024;159:107038.
    PubMed     Abstract available


  318. STAIBANO P, Au M, Xie M, Gupta MK, et al
    Return to work and self-reported swallowing following transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma: A retrospective cohort study.
    Oral Oncol. 2024;159:107033.
    PubMed     Abstract available


  319. MORTAJA S, Chiumenti FA, Kalaskar DM, Dwivedi RC, et al
    Surgical complications and functional outcomes of 3191 jejunal free flaps used for reconstruction of circumferential defects following head and neck cancer resections: A systematic review.
    Oral Oncol. 2024;160:107130.
    PubMed     Abstract available


    November 2024
  320. MARRET G, Lamy C, Vacher S, Cabel L, et al
    Deciphering molecular relapse and intra-tumor heterogeneity in non-metastatic resectable head and neck squamous cell carcinoma using circulating tumor DNA.
    Oral Oncol. 2024;160:107111.
    PubMed     Abstract available


  321. JEYARAJ G
    Letter to the editor, "Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.".
    Oral Oncol. 2024;160:107092.
    PubMed    


  322. LIU Y, Fu N, Liu H, Su S, et al
    Risk factors of lymph node metastasis in the diffuse sclerosing variant of papillary thyroid carcinoma compared with conventional papillary thyroidcarcinoma in pediatric populations.
    Oral Oncol. 2024;160:107120.
    PubMed     Abstract available


  323. YAN C, Wang R, Zhang C, Lin G, et al
    Induction chemotherapy for locally advanced nasopharyngeal carcinoma: Efficacy and safety of the TPC regimen compared to GP and TPF.
    Oral Oncol. 2024;160:107119.
    PubMed     Abstract available


  324. VON WITZLEBEN A, Grages A, Thomas J, Ezic J, et al
    Immune checkpoint expression on tumor-infiltrating lymphocytes (TIL) is dependent on HPV status in oropharyngeal carcinoma (OPSCC) - A single-cell RNA sequencing analysis.
    Oral Oncol. 2024;159:107107.
    PubMed     Abstract available


  325. LI S, Zhao T, Liu N, Li Y, et al
    Global research on oral cancer: A bibliometric analysis based on 82 highly cited publications from 2014 to 2024.
    Oral Oncol. 2024;159:107094.
    PubMed     Abstract available


  326. YANG B, Dai X, Li Z, Wu Z, et al
    Noninvasive surface-enhanced Raman spectroscopy outperforms combined positive score in predicting sensitivity to neoadjuvant immunotherapy in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107105.
    PubMed     Abstract available


  327. RENGASAMY G, Priya Veeraraghavan V
    Using salivary DNA methylation to predict aging, cell changes, and protein levels for assessing oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107086.
    PubMed    


  328. LEE YC, Hsin LJ, Lin WN, Fang TJ, et al
    Robot-assisted versus conventional neck dissection in head and neck cancers: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107101.
    PubMed     Abstract available


  329. MORGENTHALER J, Trommer M, Khor R, Wada M, et al
    Can we safely de-escalate HPV(+) oropharyngeal cancers? - A review of current practices and novel approaches.
    Oral Oncol. 2024;159:107089.
    PubMed     Abstract available


  330. LENNON SILVA CUNHA J
    In reply to "Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study".
    Oral Oncol. 2024;159:107096.
    PubMed    


  331. TOPKAN E, Somay E, Ozturk D, Selek U, et al
    Commentary on "Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions".
    Oral Oncol. 2024;159:107099.
    PubMed    


  332. SHANG K, Li T, Chen Y, Luo X, et al
    Gemcitabine plus cisplatin versus docetaxel plus cisplatin and fluorouracil induction chemotherapy combined with locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma: A single center prospective phase II clinical trial.
    Oral Oncol. 2024;159:107087.
    PubMed     Abstract available


  333. COSTANTINO A, Haughey B, Alamoudi U, Magnuson JS, et al
    Challenges in treating oropharyngeal cancer in the elderly: The role of transoral surgery.
    Oral Oncol. 2024;158:106996.
    PubMed    


  334. SOLARZ P, Mackiewicz-Nartowicz H, Sinkiewicz A, Burduk P, et al
    Results of CO2 laser surgery in laryngeal papillomatosis.
    Oral Oncol. 2024;158:107004.
    PubMed     Abstract available


  335. ASHIQUE S, Houshyari M, Islam A, Pal R, et al
    The role of microbiota in nasopharyngeal cancer: Where do we stand?
    Oral Oncol. 2024;158:106982.
    PubMed     Abstract available


  336. DE SENA COSTA DE OLIVEIRA D, Cunha JLS
    Comment on: Salivary DNA methylation derived estimates of biological aging, cellular frequency, and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107097.
    PubMed    


  337. HIMANI
    Letter to the editor: Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107093.
    PubMed    


    October 2024
  338. MUTHAMIZH S, Balachandran S, Dilipan E
    Opinion on "Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107095.
    PubMed    


  339. LEHYANTI J, Even C, Fessart E, Wagner-Ballon C, et al
    Management of oligometastatic head and neck squamous cell carcinoma: A systematic review.
    Oral Oncol. 2024;159:107085.
    PubMed     Abstract available


  340. VILLARME A, Ebran N, Pace-Loscos T, Schiappa R, et al
    Prognostic impact of intra tumoral HPV-16 viral load in oropharyngeal squamous cell carcinomas.
    Oral Oncol. 2024;159:107082.
    PubMed     Abstract available


  341. KARAMCHANDANI S, Sahovaler A, Crosbie-Jones E, McGurk M, et al
    Incidence and predictive factors for positive non-sentinel lymph nodes in completion neck dissection following a positive sentinel node biopsy in early oral cancer.
    Oral Oncol. 2024;159:107081.
    PubMed    


  342. LI D, Lopez A, Shrivastava N, Chan W, et al
    Comprehensive functional evaluation of head and neck squamous cell carcinoma with BH3-profiling demonstrates apoptotic competency and therapeutic efficacy of BH3-mimetics.
    Oral Oncol. 2024;159:107069.
    PubMed     Abstract available


  343. WU WB, Xia L, Feng ZK, Liang JL, et al
    Characteristics and treatment of epistaxis in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107071.
    PubMed     Abstract available


  344. ZANG Y, Lu Y, Yu J, Dong Q, et al
    FOXP3 inhibits proliferation and migration by competitively inhibiting YAP1 in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107066.
    PubMed     Abstract available


  345. GARSET-ZAMANI M, Lomholt AF, Charabi BW, Norling R, et al
    Surgeon-performed intraoperative transoral ultrasound improves the detection of human papillomavirus-positive head and neck cancers of unknown primary.
    Oral Oncol. 2024;159:107073.
    PubMed     Abstract available


  346. LIU C, Zhao H, Lu Y, Xia Y, et al
    Nomograms to predict occult contralateral central lymph node metastases in unilateral papillary thyroid carcinoma with ipsilateral clinical lymph node metastasis.
    Oral Oncol. 2024;159:107051.
    PubMed     Abstract available


  347. SONG Y, Zhang Y, Bai Y, Wang T, et al
    Combination kinase inhibitors and immunotherapy for unresectable anaplastic thyroid carcinoma: A retrospective single-center study.
    Oral Oncol. 2024;159:107067.
    PubMed     Abstract available


  348. AWEEDA M, Richard K, Arnaud EH, Divi V, et al
    Factors influencing lymph node yield in head and neck squamous cell carcinoma: A scoping review.
    Oral Oncol. 2024;159:107070.
    PubMed     Abstract available


  349. HE SQ, Liu GY, Yu YH, Wang L, et al
    Establishing M1 subdivision for de novo nasopharyngeal carcinoma patients receiving immuno-chemotherapy: A multicenter, retrospective cohort study.
    Oral Oncol. 2024;159:107074.
    PubMed     Abstract available


  350. LEE RH, Evans C, Alqasieer Y, Knott PD, et al
    Bite me: Can active biting during trismus therapy improve mouth opening in head and neck cancer patients?
    Oral Oncol. 2024;159:107064.
    PubMed    


  351. ZHAO BY, Hirayama S, Goss D, Zhao Y, et al
    Human papillomavirus-associated nasopharyngeal carcinoma: A systematic review and meta-analysis.
    Oral Oncol. 2024;159:107057.
    PubMed     Abstract available


  352. TANG WZ, Xu WZ, Liu TH
    Exploring the potential of gemcitabine, capecitabine, and tislelizumab after anti-PD-1 treatment in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107065.
    PubMed    


  353. YACOUB I, Qian JY, Nashed K, Youssef M, et al
    Radiation techniques and advancements in nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107060.
    PubMed    


  354. GAUDIOSO P, Contro G, Taboni S, Costantino P, et al
    Intraoperative surgical navigation as a precision medicine tool in sinonasal and craniofacial oncologic surgery.
    Oral Oncol. 2024;157:106979.
    PubMed     Abstract available


  355. DAWSON A, Karimi AH, Shaikh MH, Gazala W, et al
    Loss of MACROD2 drives radioresistance but not cisplatin resistance in HPV-positive head and neck cancer.
    Oral Oncol. 2024;159:107061.
    PubMed     Abstract available


  356. AKASHANAND, Zahiruddin QS, Jena D, Ballal S, et al
    Burden of oral cancer and associated risk factors at national and state levels: A systematic analysis from the global burden of disease in India, 1990-2021.
    Oral Oncol. 2024;159:107063.
    PubMed     Abstract available


    September 2024
  357. LECHIEN JR
    Surgical, Functional, and oncological outcomes of transoral robotic surgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;159:107047.
    PubMed     Abstract available


  358. KEEFE K, McCrary HC, Wei M, Mark B, et al
    Risk of cardiovascular disease among head and neck cancer survivors: A population-based matched cohort study.
    Oral Oncol. 2024;159:107041.
    PubMed     Abstract available


  359. DHARSHINI RAJATHIRAJAN S
    Commentary on "Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients".
    Oral Oncol. 2024;159:107053.
    PubMed    


  360. LYU W, Gong J, Zhu L, Xu T, et al
    MR radiomics unveils neoadjuvant chemo-responsiveness with insights into selective treatment de-intensification in HPV-positive oropharyngeal carcinoma.
    Oral Oncol. 2024;159:107049.
    PubMed     Abstract available


  361. PRITHVIRAJ
    Comment on "Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer".
    Oral Oncol. 2024;159:107054.
    PubMed    


  362. DINESHKUMAR R
    Letter to the editor: Risk factors associated with ototoxicity in long-term survivors of nasopharyngeal carcinoma.
    Oral Oncol. 2024;159:107052.
    PubMed    


  363. VALCENKO A, Zwick A, Schneider L, Linxweiler M, et al
    The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype.
    Oral Oncol. 2024;159:107042.
    PubMed     Abstract available


  364. MIN Y, Liu X, Wei Z, Song G, et al
    Lung immune prognostic index is associated with clinical outcomes in recurrent or metastatic (R/M) nasopharyngeal carcinoma receiving immunotherapy: Results from the multicenter, single-arm, phase 2 study.
    Oral Oncol. 2024;159:107028.
    PubMed     Abstract available


  365. RENGASAMY G, Priya Veeraraghavan V
    Comment on "The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-) radiotherapy".
    Oral Oncol. 2024;159:107035.
    PubMed    


  366. DHARSHINI RAJATHIRAJAN S
    Commentary on "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.".
    Oral Oncol. 2024;159:107037.
    PubMed    


  367. DHARSHINI RAJATHIRAJAN S
    Commentary on "Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients".
    Oral Oncol. 2024;159:107036.
    PubMed    


  368. VERSCHOOR CP, Santi SA, Singh R, Tharmalingam S, et al
    Salivary DNA methylation derived estimates of biological aging, cellular frequency and protein expression as predictors of oral mucositis severity and survival in head and neck cancer patients.
    Oral Oncol. 2024;159:107030.
    PubMed     Abstract available


  369. PAKA LUBAMBA G, Hua Y, Bao M, Zhang G, et al
    Variant of internal jugular vein reconstruction in bilateral radical neck dissection.
    Oral Oncol. 2024;159:107015.
    PubMed     Abstract available


  370. WANG A, Xia H, Li J, Diao P, et al
    Development of a novel prognostic signature derived from super-enhancer-associated gene by machine learning in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;159:107016.
    PubMed     Abstract available


  371. PRITHVIRAJ T
    Commentary on "Tumor Habitat-Based MRI features assessing early response in locally advanced nasopharyngeal carcinoma".
    Oral Oncol. 2024;159:107018.
    PubMed    


  372. XIAOYU J, Baihong P, Yaozhen L, Shen C, et al
    Preoperative protective stenting of the carotid artery in severe complex head and neck cancer resection.
    Oral Oncol. 2024;158:107012.
    PubMed     Abstract available


  373. PAYNE K, Suriyanarayanan H, Brooks J, Mehanna H, et al
    Exploring the impact of intra-tumoural heterogeneity on liquid biopsy cell-free DNA methylation and copy number in head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107011.
    PubMed     Abstract available


  374. ZHANG X, Zheng W, Huang S, Li H, et al
    Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models.
    Oral Oncol. 2024;158:107000.
    PubMed     Abstract available


  375. CHEN J, Cheng H, Liang Y, Lin J, et al
    The efficacy of adjuvant chemotherapy in patients with different midpoint-radiotherapy Epstein-Barr virus DNA plasma loads.
    Oral Oncol. 2024;156:106938.
    PubMed     Abstract available


    August 2024
  376. LECHIEN JR, Hans S
    Survival, Surgical, and functional outcomes of transoral laser microsurgery for cT1-T3 supraglottic laryngeal Cancers: A systematic review.
    Oral Oncol. 2024;158:107009.
    PubMed     Abstract available


  377. ZHAO J, Ruan X, Wei S, Zheng X, et al
    The first report of bilateral parapharyngeal lymph node metastasis from papillary thyroid carcinoma: A case report.
    Oral Oncol. 2024;158:107006.
    PubMed    


  378. YIN WJ, Mao W, Yang F, Wang MY, et al
    Effect analysis of 847 nasopharyngeal carcinoma cases treated with intensity modulated radiation: Experience and suggestions.
    Oral Oncol. 2024;158:107001.
    PubMed     Abstract available


  379. GE Y, Liu H, Huang W, Zhu H, et al
    Immunoinhibitory effects of hypoxia-driven reprogramming of EGR1(hi) and EGR3 positive B cells in the nasopharyngeal carcinoma microenvironment.
    Oral Oncol. 2024;158:106999.
    PubMed     Abstract available


  380. T P
    Commentary on "Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/mHNSCC)".
    Oral Oncol. 2024;158:107010.
    PubMed    


  381. ZHOU X, Shao T, Jia H, Hou L, et al
    Current state, challenges, and future perspective of adaptive radiotherapy: A narrative review of nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:107008.
    PubMed     Abstract available


  382. PRASAD M
    DNA Methylation Mediated Epigenetic Silencing of PD-1 and PD-L1: Therapeutic Implications in Oral Cancer.
    Oral Oncol. 2024 Aug 23:106995. doi: 10.1016/j.oraloncology.2024.106995.
    PubMed    


  383. KNAP RABJERG H, Grau Eriksen J, Soby S
    Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;158:107003.
    PubMed    


  384. DU F, Shao K, Yang Y, Bai X, et al
    Comparative dosimetric analysis of normal brain tissue in patients with Nasopharyngeal carcinoma at different stages after radiation therapy.
    Oral Oncol. 2024;158:106998.
    PubMed     Abstract available


  385. ALSHEIKH S, Su J, O'Sullivan B, Ringash J, et al
    The prognostic value of image-identified extranodal extension in laryngeal and hypopharyngeal carcinoma following definitive (chemo-)radiotherapy.
    Oral Oncol. 2024;158:107007.
    PubMed     Abstract available


  386. SUN L, Cohen RB, Dimitrios Colevas A
    Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC).
    Oral Oncol. 2024;158:106997.
    PubMed     Abstract available


  387. HANNA GJ, Jabalee J, Lukens JN, Sun L, et al
    Circulating tumor tissue modified viral (TTMV)-HPV DNA in Recurrent, metastatic HPV-driven oropharyngeal cancer.
    Oral Oncol. 2024;158:107002.
    PubMed     Abstract available


  388. YUAN J, Wu M, Qiu L, Xu W, et al
    Tumor habitat-based MRI features assessing early response in locally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;158:106980.
    PubMed     Abstract available


  389. YANG R, Li R, Niu X, Zhao Y, et al
    Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.
    Oral Oncol. 2024;158:106981.
    PubMed     Abstract available


  390. HUSSEIN NI, Molina AH, Sunga GM, Amit M, et al
    Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;158:106986.
    PubMed     Abstract available


  391. PAN GS, Sun XM, Kong FF, Wang JZ, et al
    Delta magnetic resonance imaging radiomics features?based nomogram predicts long?term efficacy after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106987.
    PubMed     Abstract available


  392. QIN G, Liao X, Zhang B, Su Y, et al
    An individualized immune prognostic signature in nasopharyngeal carcinoma.
    Oral Oncol. 2024;157:106985.
    PubMed     Abstract available


  393. TAMIOLAKIS P, Shah A, Dawson R, Ramasamy S, et al
    HPV- associated sinonasal squamous cell carcinoma with FGFR3::TACC3 fusion. A rare case report.
    Oral Oncol. 2024;157:106983.
    PubMed     Abstract available


  394. SHIMIZU H, Kodaira T, Kiyota N, Hayashi R, et al
    Incidence and risk factors associated with the development of hypothyroidism after postoperative chemoradiotherapy for head and neck cancer patients with high-risk features: Supplementary analysis of JCOG1008.
    Oral Oncol. 2024;157:106976.
    PubMed     Abstract available


  395. SANKAR S
    Letter to editor regarding "Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression".
    Oral Oncol. 2024;157:106977.
    PubMed    


  396. SCHAEFFERS AWMA, Scholten HA, van Beers MA, Meussen BW, et al
    The effect of skeletal muscle mass on dose-limiting toxicities during (chemo)radiotherapy in patients with head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;157:106978.
    PubMed     Abstract available


    July 2024
  397. MCDOWELL L, Gough K, White I, Corry J, et al
    Sexual Health, sexuality and sexual intimacy in patients with head and neck cancer - A narrative review.
    Oral Oncol. 2024;157:106975.
    PubMed     Abstract available


  398. DAS S, Ghosh Laskar S, V Kane S, D'Cruz AK, et al
    Adjuvant therapy for intermediate risk factors in oral cancer: Can we reach a consensus?
    Oral Oncol. 2024;157:106972.
    PubMed     Abstract available


  399. JEYARAJ G
    Letter to the editor, "Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the head and neck Cancer Registry of Japan.".
    Oral Oncol. 2024;157:106974.
    PubMed    


  400. JEYARAJ G
    Letter to the editor, "Mutation detection in saliva from oral cancer patients".
    Oral Oncol. 2024;157:106929.
    PubMed    


  401. GANESH PS, Pathoor NN, Gopal RK
    Letter to the editor regarding "Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;157:106954.
    PubMed     Abstract available


  402. LORINI L, Zigliani G, Morbini P, Salviato E, et al
    Expression of PDL-1 between primary and recurrent/metastatic head and neck squamous cell carcinoma: A bi-institutional retrospective concordance analysis (CONCORDL-1 study).
    Oral Oncol. 2024;157:106950.
    PubMed     Abstract available


  403. JEYACHANDRAN S
    Comment on, "Characterization of oral microbiota in HPV and non-HPV head and neck squamous cell carcinoma and its association with patient outcomes".
    Oral Oncol. 2024;157:106973.
    PubMed     Abstract available


  404. SURESH S
    Comment on: An algorithm for standardization of tumor infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;157:106959.
    PubMed    


  405. WEN YF, Huang WJ, Chen XL, Cai HT, et al
    Predictive value of CXCL1(+)_FAP(+) phenotype in CAFs for distant metastasis and its correlation with PD-L1 expression in locoregionally advanced nasopharyngeal carcinoma patients.
    Oral Oncol. 2024;157:106963.
    PubMed     Abstract available


  406. ICHISAKA T, Sano D, Kijima N, Kawakita D, et al
    Clinical benefits of combining oral cytotoxic chemotherapeutic agents with radiotherapy in patients with T2N0 glottic squamous cell carcinoma based on the reports of the Head and Neck Cancer Registry of Japan.
    Oral Oncol. 2024;157:106942.
    PubMed     Abstract available


  407. TINO R, Roach MA, Fuentes GD, Agrawal A, et al
    Development and clinical implementation of a digital workflow utilizing 3D-printed oral stents for patients with head and neck cancer receiving radiotherapy.
    Oral Oncol. 2024;157:106944.
    PubMed     Abstract available


  408. LIM CY, Ng GWY, Goh CK, Lee MKC, et al
    Impact of high-risk EBV strains on nasopharyngeal carcinoma gene expression.
    Oral Oncol. 2024;157:106941.
    PubMed     Abstract available


  409. SHANMUGAM G
    Letter to the editor, "The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.".
    Oral Oncol. 2024;157:106951.
    PubMed    


  410. MEIVELU MOOVENDHAN
    "Letter to the Editor: Next-Generation sequencing (NGS) profiling of matched tumor and Circulating Tumor DNA (ctDNA) in Head and Neck Squamous Cell Carcinoma (HNSCC)".
    Oral Oncol. 2024;157:106940.
    PubMed    


  411. ZENGA J, Himburg HA, Wong SJ, Kearl T, et al
    In silico identification of public neo-antigens in head and neck Cancer for T cell receptor Engineering: Targeting PI3KCA and TP53 missense mutations.
    Oral Oncol. 2024 Jul 14:106947. doi: 10.1016/j.oraloncology.2024.106947.
    PubMed    


  412. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "Immunochemotherapy alone or immunochemotherapy plus subsequent locoregional radiotherapy in de novo metastatic nasopharyngeal carcinoma".
    Oral Oncol. 2024;156:106948.
    PubMed    


  413. SHANMUGAM G
    Commentary on, "Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.".
    Oral Oncol. 2024;156:106952.
    PubMed    


  414. PIYARATHNE NS, Liyanage SN, Rasnayaka RMSGK, Hettiarachchi PVKS, et al
    A comprehensive dataset of annotated oral cavity images for diagnosis of oral cancer and oral potentially malignant disorders.
    Oral Oncol. 2024;156:106946.
    PubMed     Abstract available


  415. MAHDI AGM
    Knowledge, and attitude of medical students about role of human papilloma virus, and vaccine in head and neck cancer.
    Oral Oncol. 2024;156:106939.
    PubMed     Abstract available


  416. SHANMUGAM G
    Letter to the editor, "Letter to the editor, "Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.".
    Oral Oncol. 2024;156:106935.
    PubMed    


  417. ARUMUGANAINAR D, Sekaran S
    Correspondence on "Global burdens of nasopharyngeal carcinoma in children and young adults: Trends and predictions to 2040".
    Oral Oncol. 2024;156:106933.
    PubMed    


  418. GU LW, Zhang X, Zhang J, Xiao BB, et al
    The prognostic value of pretreatment (18)F-FDG PET-CT parameters with peripheral blood markers in patients with de novo metastatic nasopharyngeal carcinoma.
    Oral Oncol. 2024;156:106928.
    PubMed     Abstract available


  419. SURESH S
    Commentary on 'Mutation detection in saliva from oral cancer patients'.
    Oral Oncol. 2024;156:106937.
    PubMed    


  420. KASIRAJAN H, Rengasamy G, Priya Veeraraghavan V
    Comment on the "Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module".
    Oral Oncol. 2024;156:106934.
    PubMed    


  421. KANNAN R
    Comments on: Human Papilloma Virus vaccine and prevention of head and neck cancer, what is the current evidence?
    Oral Oncol. 2024;156:106936.
    PubMed    


  422. DAUNGSUPAWONG H, Wiwanitkit V
    Letter to the Editor on "Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance".
    Oral Oncol. 2024;156:106930.
    PubMed    


  423. LIOKATIS P, Liokati I, Obermeier K, Smolka W, et al
    Prognostic role of lymph node micrometastasis in oral and oropharyngeal cancer: A systematic review.
    Oral Oncol. 2024;154:106808.
    PubMed     Abstract available


  424. CHEN AM
    Translational risk-adapted approaches to de-escalated radiation for human papillomavirus-positive oropharyngeal cancer: Past, present, and future.
    Oral Oncol. 2024;154:106850.
    PubMed     Abstract available


  425. SATHISHKUMAR K
    Letter to the editor "risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial ".
    Oral Oncol. 2024;156:106931.
    PubMed    


  426. HARIDEVAMUTHU B
    Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
    Oral Oncol. 2024;156:106913.
    PubMed    


    June 2024
  427. BENJAMIN WJ, Feng AL, Heft Neal M, Bellile E, et al
    Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer.
    Oral Oncol. 2024;156:106917.
    PubMed     Abstract available


  428. ZHAO X, Zhou Y, Peng G, Wen L, et al
    Final analysis of a phase II trial of neoadjuvant chemoimmunotherapy for locoregionally advanced head and neck squamous cell carcinoma.
    Oral Oncol. 2024;156:106918.
    PubMed     Abstract available


  429. SARAVANAN M, Singh Carmelin D, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;156:106911.
    PubMed    


  430. POONGAVANAM SS, Behera A, Dharmalingam Jothinathan MK
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;156:106912.
    PubMed    


  431. JEYARAJ G
    Letter to the editor, "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer".
    Oral Oncol. 2024;156:106906.
    PubMed    


  432. DONG S, Bei W, Lin L, Jiang Y, et al
    Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study.
    Oral Oncol. 2024;156:106908.
    PubMed     Abstract available


  433. JEYARAJ G
    Transformative impact of 3D-Printed implants and Virtual surgical planning in oral cancer reconstruction.
    Oral Oncol. 2024;156:106896.
    PubMed    


  434. SHANMUGAM G
    Letter to the editor, "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.".
    Oral Oncol. 2024;156:106915.
    PubMed    


  435. BASTIEN AJ, Ng J, Cong I, Garcia J, et al
    Patient perceptions underlying ctDNA molecular surveillance for HPV(+) oropharyngeal squamous cell carcinoma.
    Oral Oncol. 2024;156:106894.
    PubMed     Abstract available


  436. HARIDEVAMUTHU B
    Letter to the Editor: "Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral Cancer".
    Oral Oncol. 2024;155:106902.
    PubMed    


  437. MEIVELU MOOVENDHAN
    Letter to the editor, "Gut microbiome predicts gastrointestinal toxicity outcomes from chemoradiation therapy in patients with head and neck squamous cell carcinoma".
    Oral Oncol. 2024;155:106903.
    PubMed    


  438. PRASAD M, Sekar R, Murugan R
    Letter to editor on "Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer".
    Oral Oncol. 2024;155:106899.
    PubMed    


  439. SELVI POONGAVANAM S, Behera A, Kumar Dharmalingam Jothinathan M
    Letter to the Editor, "The predictive role of PD-L1 in head and neck Cancer: A systematic review and Meta-Analysis".
    Oral Oncol. 2024;155:106904.
    PubMed    


  440. TOPKAN E, Somay E, Bascil S, Selek U, et al
    Comment on prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;155:106898.
    PubMed    


  441. HARIDEVAMUTHU B
    Genomic instability in HPV-positive oropharyngeal squamous cell carcinoma: The role of integration sites in treatment response.
    Oral Oncol. 2024;155:106895.
    PubMed    


  442. LEI S, Chen L, Ji P, Li K, et al
    Global burdens of nasopharyngeal carcinoma in children and young adults and predictions to 2040.
    Oral Oncol. 2024;155:106891.
    PubMed     Abstract available


  443. DA MOTA SANTANA LA, Simoes JMD, Santos GA, Gopalsamy RG, et al
    Comment on "Association between COVID 19 exposure and expression of malignant pathological features in oral cancer: A retrospective cohort study".
    Oral Oncol. 2024;155:106877.
    PubMed    


  444. ROOF SA, Jabalee J, Rettig EM, Chennareddy S, et al
    Utility of TTMV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.
    Oral Oncol. 2024;155:106874.
    PubMed     Abstract available


  445. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    Corrigendum to "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group" [Oral Oncol. 152C (2024) 106744].
    Oral Oncol. 2024 Jun 8:106887. doi: 10.1016/j.oraloncology.2024.106887.
    PubMed    


  446. PRASAD M, Murugan R
    Comment on "The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis".
    Oral Oncol. 2024;155:106890.
    PubMed    


  447. TASOULAS J, Adams GJ, Schrank TP, Agala CB, et al
    Time to treatment for head and neck cancer patients decreased during the early phase of the Covid-19 pandemic.
    Oral Oncol. 2024;155:106879.
    PubMed    


  448. DHARMALINGAM JOTHINATHAN MK
    Letter to the Editor, "How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? A multi-institutional study on 366 patients from the ARYFIX collaborative group".
    Oral Oncol. 2024;155:106878.
    PubMed    


  449. BABU S, Krishnan M
    Human papillomavirus and oropharyngeal cancer in HNSCC: A growing concern.
    Oral Oncol. 2024;153:106824.
    PubMed    


  450. PACE GM, Costantino A, Festa BM, Spriano G, et al
    Oropharyngeal squamous cell carcinoma: Treatment (de-) intensification?
    Oral Oncol. 2024;153:106299.
    PubMed    


  451. LU HA, Wang YM, Chih Chen W, Wu CN, et al
    Post-irradiation dysbiosis in patients with nasopharyngeal carcinoma having received radiotherapy - A pilot study.
    Oral Oncol. 2024;154:106864.
    PubMed     Abstract available


  452. KRC R, Mendes W, Molitoris J, Ferris M, et al
    Proton therapy re-irradiation outcomes and genomic landscape of patients with recurrent head and neck cancer.
    Oral Oncol. 2024;154:106875.
    PubMed     Abstract available


    May 2024
  453. XU W, Qiu L, Li F, Fei Y, et al
    Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Oral Oncol. 2024;154:106865.
    PubMed     Abstract available


  454. IMAMURA Y, Kiyota N, Tahara M, Kodaira T, et al
    Risk prediction model for cisplatin-induced acute kidney injury in patients with head and neck cancer receiving chemoradiotherapy: A re-analysis of a phase II/III JCOG1008 trial.
    Oral Oncol. 2024;154:106868.
    PubMed     Abstract available


  455. PARK R, Li J, Slebos RJC, Chaudhary R, et al
    Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
    Oral Oncol. 2024;154:106866.
    PubMed     Abstract available


  456. SARAVANAN M, Carmelin DS, Mohanprasanth A, Arockiaraj J, et al
    Comment on "Oral microbiome and risk of incident head and neck cancer: A nested case-control study".
    Oral Oncol. 2024;154:106858.
    PubMed    


  457. HESHAM A, David Kim D, Alshamrani Y, AlOtaibi F, et al
    The efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy in recurrent head and neck squamous cell carcinoma. Report of a case and review of the literature.
    Oral Oncol. 2024;154:106863.
    PubMed    


  458. ABBACI M, Villard A, Auperin A, Asmandar S, et al
    Ultra-fast confocal fluorescence microscopy for neck lymph node imaging in head and neck cancer.
    Oral Oncol. 2024;154:106862.
    PubMed     Abstract available


  459. YAO Y, Ouyang Q, Wang S, Li K, et al
    Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
    Oral Oncol. 2024;154:106867.
    PubMed     Abstract available


  460. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    In response to the reply on 'Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes'.
    Oral Oncol. 2024;154:106856.
    PubMed    


  461. COSTANTINO A, Haughey B, Zhu J, Mekhail T, et al
    Sinonasal squamous cell carcinoma in the United States: Temporal and geographic patterns associated with HPV testing and positivity.
    Oral Oncol. 2024;154:106855.
    PubMed     Abstract available


  462. PEZZULLA D, Re A, Ferro M, Cilla S, et al
    Lower cranial nerve palsy after hypofractionated radiotherapy in a laryngeal cancer patient: A letter to the editor.
    Oral Oncol. 2024;154:106837.
    PubMed    


  463. ALVES DA MOTA SANTANA L, Gois Floresta L, Maciel Alves EV, Ribeiro Couto G, et al
    Reply to: Comment on "Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes".
    Oral Oncol. 2024;154:106840.
    PubMed    


  464. HE S, Yu H, He L, Liu M, et al
    Risk factors associated with ototoxicity in long-term nasopharyngeal carcinoma survivors.
    Oral Oncol. 2024;154:106827.
    PubMed     Abstract available


  465. VAZQUEZ FL, Coracin FL, Arantes KLBF, Ferigatto JL, et al
    An oral cancer screening program in Brazil: Analysis of seven years of outcome after its implementation in the suburban cities of Sao Paulo.
    Oral Oncol. 2024;154:106826.
    PubMed     Abstract available


  466. DE FELICE F, Guerrero Urbano T
    Lower-neck sparing in patients with uninvolved neck nasopharyngeal carcinoma: Unquestioned benefit?
    Oral Oncol. 2024;154:106836.
    PubMed    


  467. HAN N, Zhou D, Ruan M, Yan M, et al
    Corrigendum to "Cancer cell-derived extracellular vesicles drive pre-metastatic niche formation of lymph node via IFNGR1/JAK1/STAT1-activated-PD-L1 expression on FRCs in head and neck cancer" [Oral Oncol. 145 (2023) 106524].
    Oral Oncol. 2024 May 9:106831. doi: 10.1016/j.oraloncology.2024.106831.
    PubMed    


  468. INVERNIZZI C, Da Silva Ribeiro Mota A, Barbe C, Bouazzi L, et al
    Prospective comparison of acute severe toxicities between smokers and non-smokers during radiotherapy for head and neck cancers.
    Oral Oncol. 2024;153:106833.
    PubMed     Abstract available


  469. PADERNO A, Petrelli F, Lorini L, Capriotti V, et al
    The predictive role of PD-L1 in head and neck cancer: A systematic review and meta-analysis.
    Oral Oncol. 2024;153:106799.
    PubMed     Abstract available


  470. LIU Y, Zuo ZC, Zeng XY, Ma J, et al
    Establishing subdivisions of M1 stage nasopharyngeal carcinoma based on decision tree classification: A multicenter retrospective study.
    Oral Oncol. 2024;153:106834.
    PubMed     Abstract available


  471. XU Y, Xu T, Yao Q, Chen J, et al
    Individualized radiology screening for newly diagnosed nasopharyngeal carcinoma.
    Oral Oncol. 2024;153:106828.
    PubMed     Abstract available


  472. ALMANGUSH A, Makitie AA, Leivo I
    Assessment of tumor-infiltrating lymphocytes in head and neck cancer: Clinical scenarios.
    Oral Oncol. 2024;153:106829.
    PubMed    


  473. DAS R, Misra SR
    Author's reply to comment on "awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;153:106832.
    PubMed    


  474. DHARMALINGAM JOTHINATHAN MK
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106811.
    PubMed    


  475. POOJARI M, Madabhavi I, Desai S
    Extraskeletal Ewing's sarcoma of supraglottis: A rare case report.
    Oral Oncol. 2024;152:106789.
    PubMed     Abstract available


  476. MELDGAARD JUSTESEN M, Kronberg Jakobsen K, Fenger Carlander AL, Hjordt Holm Larsen M, et al
    Outcomes of transoral robotic surgery for early-stage oropharyngeal squamous cell carcinoma with low rates of adjuvant therapy: A consecutive single-institution study from 2013 to 2020.
    Oral Oncol. 2024;152:106783.
    PubMed     Abstract available


    April 2024
  477. TONSBEEK AM, Hundepool CA, Roubos J, Rijken B, et al
    Quality of life in 583 head and neck cancer survivors assessed with the FACE-Q head and neck cancer module.
    Oral Oncol. 2024;153:106813.
    PubMed     Abstract available


  478. MICHIKAWA C, Gleber-Netto FO, Pickering CR, Rao X, et al
    Immune infiltration at the primary tumor is associated with clinical outcome of patients with extranodal extension of lymph node metastasis in oral cancer.
    Oral Oncol. 2024;153:106729.
    PubMed     Abstract available


  479. FANG Q, Yuan J, Zhang X, Dai L, et al
    Oncologic and functional results between sentinel lymph node biopsy and elective neck dissection in cT1/2N0 maxillary squamous cell carcinoma.
    Oral Oncol. 2024;152:106810.
    PubMed     Abstract available


  480. YEO BSY, Lee RS, Lim NE, Tan E, et al
    Efficacy and Safety of Cell-based Immunotherapy in The Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma - A Systematic Review and Meta-analysis.
    Oral Oncol. 2024;152:106786.
    PubMed     Abstract available


  481. LI Y, Zhou Y, Zhao C, Liu L, et al
    The circadian clock gene, BMAL1, promotes radiosensitization in nasopharyngeal carcinoma by inhibiting the epithelial-to-mesenchymal transition via the TGF-beta1/Smads/Snail1 axis.
    Oral Oncol. 2024;152:106798.
    PubMed     Abstract available


  482. RAMASAMY P, Sekaran S, Ganapathy D
    Oral cancer burden in tribal populations residing in India.
    Oral Oncol. 2024;152:106801.
    PubMed    


  483. SEKAR D
    Comment on betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106800.
    PubMed    


  484. SARAVANAN M
    Comment on "Nanomedicine, an emerging therapeutic strategy for oral cancer therapy".
    Oral Oncol. 2024;152:106806.
    PubMed    


  485. RICARDO ELIAS DE MELO P, Agra Monteiro M, Henrique Rocha Aragao H, Vitoria de Araujo Lopes N, et al
    Comment on "Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?".
    Oral Oncol. 2024;152:106802.
    PubMed    


  486. SMITH JD, Heft-Neal ME, Rosko AJ, Chepeha DB, et al
    Upfront neck dissection to guide single-modality therapy for early stage supraglottic squamous cell carcinoma.
    Oral Oncol. 2024;152:106803.
    PubMed    


  487. KONO M, Saito S, Rokugo M, Egloff AM, et al
    Enhanced oral versus flank lymph node T cell response parallels anti-PD1 efficacy in head and neck cancer.
    Oral Oncol. 2024;152:106795.
    PubMed     Abstract available


  488. SEGNA E, Civita F, Denaro N, Beltramini GA, et al
    Cavernous sinus metastasis in head and neck cancer: Focus on oral squamous cell cancer.
    Oral Oncol. 2024;152:106784.
    PubMed     Abstract available


  489. SIVAPERUMAL P, Ganapathy D, Kamala K
    Revolutionizing oral cancer treatment: Harnessing the potential of adaptive CARneg T cell therapy.
    Oral Oncol. 2024;152:106794.
    PubMed    


  490. RAJAKUMAR HK, Coimbatore Sathyabal V, Vivekanandam A, Nasrin Jabarulla K, et al
    Evaluation of nuclear morphometry in exfoliative cytology of buccal mucosa in patients with high risk of oral cancer.
    Oral Oncol. 2024;152:106793.
    PubMed     Abstract available


  491. SARAVANAN M
    Comment on "The microbiome and oral cancer: More questions than answers".
    Oral Oncol. 2024;152:106792.
    PubMed    


  492. ARAGAO HHR, Monteiro MA, Lopes NVA, Cunha JLS, et al
    Comment on "Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study".
    Oral Oncol. 2024;152:106788.
    PubMed    


  493. DAS R, Misra SR, Nayak A
    Awareness regarding oral cancer amongst the dental, medical, and nursing students: Is something lacking?
    Oral Oncol. 2024;152:106790.
    PubMed    


  494. XIAO X, Shi Z, Song Z
    Comment on circulatory mitochondrial DNA as a novel biomarker for head and neck cancers.
    Oral Oncol. 2024;152:106785.
    PubMed    


  495. GASNE C, Atallah S, Dauzier E, Thariat J, et al
    Twelve years after: The french national network on rare head and neck tumours (REFCOR).
    Oral Oncol. 2024;151:106762.
    PubMed     Abstract available


  496. MALI SB
    Role of telemedicine in head neck cancer.
    Oral Oncol. 2024;151:106746.
    PubMed     Abstract available


  497. MIRIMOGHADDAM M, Bohlouli B, Lai H, Viegas S, et al
    Trends and predictors of unplanned hospitalization among oral and oropharyngeal cancer patients; an 8-year population-based study.
    Oral Oncol. 2024;151:106742.
    PubMed     Abstract available


    March 2024
  498. MEGAHED R, Prabhu AV, Mack DP, Gholami S, et al
    Re-irradiation of recurrent head and neck cancers using pulsed reduced dose rate radiotherapy: An institutional series.
    Oral Oncol. 2024;152:106778.
    PubMed     Abstract available


  499. LORINI L, Gili R, Salvestrini V, Morelli I, et al
    De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
    Oral Oncol. 2024;152:106768.
    PubMed     Abstract available


  500. XIROU V, Moutafi M, Bai Y, Nwe Aung T, et al
    An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.
    Oral Oncol. 2024;152:106750.
    PubMed     Abstract available


  501. HONG RL, Yen CJ, Lien MY, Cheng R, et al
    Betel-nut chewing does not influence PD-L1 expression rates in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC): A prospective biomarker prevalence study.
    Oral Oncol. 2024;152:106760.
    PubMed     Abstract available


  502. FERRARI M, Mularoni F, Taboni S, Crosetti E, et al
    How reliable is assessment of true vocal cord-arytenoid unit mobility in patients affected by laryngeal cancer? a multi-institutional study on 366 patients from the ARYFIX collaborative group.
    Oral Oncol. 2024;152:106744.
    PubMed     Abstract available


  503. TOYA R, Fukugawa Y, Saito T, Matsuyama T, et al
    Radiation Therapy Oncology Group 8502 "QUAD shot" regimen using volumetric modulated arc therapy for incurable head and neck cancer.
    Oral Oncol. 2024;151:106752.
    PubMed     Abstract available


  504. RUIZ-TORRES DA, Naegele S, Podury A, Wirth L, et al
    Immunotherapy time of infusion impacts survival in head and neck cancer: A propensity score matched analysis.
    Oral Oncol. 2024;151:106761.
    PubMed     Abstract available


  505. SIMON L, Paly J, Park E, Samuels-Kalow M, et al
    Medicare dental coverage for patients with head and neck cancer: An opportunity in need of advocates.
    Oral Oncol. 2024 Mar 15:106754. doi: 10.1016/j.oraloncology.2024.106754.
    PubMed    


  506. RICARDO ELIAS DE MELO P, Agra Monteiro M, Vitoria de Araujo Lopes N, Silva Cunha JL, et al
    Comment on "advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with Teledentistry for Better Patient Outcomes".
    Oral Oncol. 2024;151:106758.
    PubMed    


  507. RAJANATHADURAI J, Sindya J, Madar IH, Perumal E, et al
    Exosomal immune checkpoint protein (PD-L1): Hidden player in PD-1/PD-L1 blockade immunotherapy resistance in oral cancer.
    Oral Oncol. 2024;151:106748.
    PubMed    


  508. ZUPANCIC M, Kostopoulou ON, Holzhauser S, Lukoseviciute M, et al
    Human papillomavirus (HPV) load is higher in HPVDNA/p16 positive than in HPVDNA positive/p16 negative oropharyngeal squamous cell carcinoma but does not differ significantly between various subsites or correlate to survival.
    Oral Oncol. 2024;151:106749.
    PubMed     Abstract available


  509. FERRARO T, Pershad AR, Arora S, Lee E, et al
    The utility of ultrasonographic surveillance in management of a presumed branchial cleft cyst later confirmed HPV-associated oropharyngeal cancer.
    Oral Oncol. 2024;151:106743.
    PubMed     Abstract available


  510. KIM DH, Lim ST, Kim HR, Kang EJ, et al
    Impact of PIK3CA and cell cycle pathway genetic alterations on durvalumab efficacy in patients with head and neck squamous cell carcinoma: Post hoc analysis of TRIUMPH study.
    Oral Oncol. 2024;151:106739.
    PubMed     Abstract available


  511. SANTANA LADM, Floresta LG, Alves EVM, Melo LMR, et al
    Advancing oral cancer diagnosis in Brazil: Integrating artificial intelligence with teledentistry for enhanced patient outcomes.
    Oral Oncol. 2024;151:106741.
    PubMed    


  512. CHEN K, Shi M, Mo S, Liu T, et al
    Clinical features and prognostic factors of nasopharyngeal carcinoma with brain metastases.
    Oral Oncol. 2024;151:106738.
    PubMed     Abstract available


  513. DING C, Dai DY, Luo ZK, Wang GY, et al
    Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
    Oral Oncol. 2024;151:106725.
    PubMed     Abstract available


  514. LU X, Zhang JL, Zhai X, Liu Q, et al
    A case report on a nasal and oral cavity involving large solitary fibrous tumor and comprehensive review of case literature.
    Oral Oncol. 2024;150:106715.
    PubMed     Abstract available


  515. YOUNG RJ, Angel C, Bressel M, Pizzolla A, et al
    Characterising B cell expression and prognostic significance in human papillomavirus positive oropharyngeal cancer.
    Oral Oncol. 2024;150:106687.
    PubMed     Abstract available


    February 2024
  516. VAN SCHAIK JE, van der Vegt B, Slagter-Menkema L, van der Laan BFAM, et al
    Identification of new head and neck squamous cell carcinoma molecular imaging targets.
    Oral Oncol. 2024;151:106736.
    PubMed     Abstract available


  517. MELACHURI M, Kurukulasuriya C, Rumde P, Patel T, et al
    Treatment package time < 14 weeks improves recurrence free and disease specific survival in HPV positive OPC with high-risk features.
    Oral Oncol. 2024;151:106703.
    PubMed     Abstract available


  518. AHMED AA, Sborchia M, Bye H, Roman-Escorza M, et al
    Mutation detection in saliva from oral cancer patients.
    Oral Oncol. 2024;151:106717.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Otorhinolaryngology is free of charge.

Privacy / Datenschutzerklärung | Imprint / Impressum